Molecular determinants of the response to malaria therapeutics by Cavaco, Isa da Conceição Lopes
 UNIVERSIDADE DO ALGARVE 
FACULDADE DE CIÊNCIAS E TECNOLOGIA 
 
 
 
 
 
 
MOLECULAR DETERMINANTS OF THE 
RESPONSE TO MALARIA THERAPEUTICS 
(Tese para a obtenção do grau de doutor no ramo de Bioquímica, 
especialidade de Biologia Celular e Molecular) 
 
 
 
Isa da Conceição Lopes Cavaco 
 
 
 
 
Orientador: Doutora Vera Linda Ribeiro Marques 
Co-orientador: Doutor José Pedro Planco Panades Gil 
  
 
Constituição do Júri:  
Doutor Anders Björkman, Doutor Adrián Llerena Ruiz, Doutor Virgílio Estólio 
do Rosário, Doutor José Pedro Planco Panades Gil, Doutora Margarida Sofia 
Pereira Duarte Amaral Cardoso Botelho, Doutora Vera Linda Ribeiro Marques, 
Doutor Paulo José Garcia de Lemos Trigueiros de Martel 
 
Presidente: Professor Doutor João Pinto Guerreiro 
Vogais: Professores Doutores Adrián Llerena Ruiz e Virgílio Estólio do Rosário 
 
 
 
FARO 
(2007) 
  i
NOME: Isa da Conceição Lopes Cavaco 
FACULDADE: Faculdade de Ciências e Tecnologia 
ORIENTADOR: Doutora Vera Linda Ribeiro Marques 
CO-ORIENTADOR: Doutor José Pedro Planco Panades Gil  
DATA: 5 de Junho de 2007 
TÍTULO DA TESE:  
 “Determinantes moleculares da resposta à terapêutica na malária” 
RESUMO 
O objectivo geral desta tese foi a análise da variabilidade genética em genes que 
codificam proteínas importantes no metabolismo de xenobióticos. A análise do 
metabolismo de antimaláricos, em particular da amodiaquina, e a possível contribuição 
da biotransformação para a susceptibilidade para a doença foi também avaliada. 
Os resultados obtidos na análise de genótipos em populacões da Guiné-Bissau, 
Portugal, São Tomé e Príncipe, Tailândia e Zanzibar revelaram uma grande 
variabilidade inter-étnica. Uma grande variabilidade foi também observada entre as 
diferentes populacões Africanas. O estudo dos genótipos CYP2C8 em indivíduos 
tratados com amodiaquina revelou que nenhum dos alelos analisados influencia a 
eficácia da terapêutica.  
Na análise do metabolismo da amodiaquina estudou-se em particular o 
metabolito desetilamodiaquina. Utilizando microssomas enriquecidos com CYPs 
recombinantes, foi observada uma redução na concentração de fármaco na presença do 
CYP1A1. A procura de variabilidade genética no CYP1A1 identificou vários SNPs, em 
particular numa população da Papua Nova Guiné. Porém, esta variabilidade não se 
mostrou associada aos extremos observados nos parâmetros farmacocinéticos. 
O estudo da influência do genótipo “null” GSTT1 na malária não-severa revelou 
que a delecção do gene poderá constituir um factor protector para a doença.  
 
Palavras-chave: Farmacogenética, Malária, Amodiaquina, Desetilamodiaquina, 
Metabolismo de xenobióticos 
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TÍTULO DA TESE EM INGLÊS:  
“Molecular determinants of the response to malaria therapeutics” 
 
ABSTRACT 
The overall aim of this thesis was the analysis of the genetic variability in genes 
coding for proteins important in drug metabolism. The analysis of the metabolism of 
antimalarial drugs, particularly amodiaquine, and the possible contribution of 
biotransformation for the susceptibility to the disease was also studied.   
The results obtained in the genotyping studies in the populations of Guinea-
Bissau, Portugal, Sao Tome and Principe, Thailand and Zanzibar showed a high 
interethnic variability. A high variability in Africans was observed. The study of the 
effect of CYP2C8 genotype in the AQ treatment outcome revealed that none of the 
alleles analysed influence therapeutic efficacy. 
In the analysis of amodiaquine metabolism we focused particularly on the 
metabolite desethylamodiaquine. Using microsomes enriched with recombinant CYPs, 
a reduction in drug concentration was observed in the presence of CYP1A1. The 
posterior investigation of the genetic variation in CYP1A1 identified several SNPs, 
particularly in the Papua New Guinea population. However, this variability could not 
be associated with the extreme variability observed in pharmacokinetic parameters.  
The study on the influence of the GSTT1 null genotype in uncomplicated 
malaria revealed that the lack of this gene seems to be a protective factor in this 
disease.  
 
Keywords: Pharmacogenetics, Malaria, Amodiaquine, Desethylamodiaquine, Drug 
metabolism 
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INTRODUCTION 
 
General Background 
 
 The first description of individual idiosyncratic reactions to xenobiotics goes 
back to the year of 510 B.C. when Pythagoras identified potentially fatal reactions in 
some individuals after the ingestion of fava beans (Nebert, 1999). The cause of this 
adverse reaction was identified in 1956 when African American US Army soldiers had 
adverse effects after the intake of the antimalarial drug primaquine and during a high 
altitude flight. These were attributed to a deficiency in erythrocyte glucose 6-phosphate 
dehydrogenase (G6PD) activity (Carson et al., 1956).  
The concept behind the variability observed was pharmacogenetics, defined in 
1959 by Friedrich Vogel as the “study of the role of variability in drug response due to 
heredity” (Vogel, 1959; Nebert, 1999).  
 Pharmacogenetics related to drug metabolism is an important field of research, 
but to understand the processes that follow drug administration it is also necessary to 
know what happens in terms of pharmacokinetics and pharmacodynamics. 
Pharmacokinetics describes the process of absorption, distribution, metabolism and 
excretion of a drug in the body. Pharmacodynamics describes the pharmacological 
effect of a drug in the body or disease causing pathogen and, subsequently, the effect on 
the clinical phenotype. 
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Pharmacokinetic Aspects 
 
 Drugs must enter the bloodstream after administration to be distributed to the 
site of action. Absorption is defined as the process by which unchanged drug proceeds 
from the site of administration to the site of measurement within the body (Rowland and 
Tozer, 1995). Absorption is not an intervening factor if the drug is given intravenously, 
but in the case of oral ingestion, for example, the drug needs to be absorbed from the 
gut. The absorption process mostly happens though passive diffusion where no energy 
is required for the process, but active transporters can also be involved and this is an 
energy-dependent process across the membrane. The extent of absorption determines 
the fraction of a dose that gains access to the circulation (bioavailability). For some 
drugs bioavailability may be influenced by metabolism in the gut and liver before 
reaching the systemic circulation, since these tissues are sites of elimination. This 
process reduces the amount of drug reaching the systemic circulation and is called first-
pass effect (Rowland and Tozer, 1995). 
 When the drug reaches the systemic circulation, it is distributed throughout the 
body into different conceptual body compartments (e.g. plasma water, interstitial fluid, 
intracellular water or fat). The distribution is dependent on the lipid solubility of the 
drug, concentration in plasma and in various tissues, permeability of tissue membranes, 
blood perfusion and binding of the drug to plasma proteins and/or transport proteins. 
The binding is a reversible process with the unbound drug usually being the actual 
pharmacologic action agent (Buxton, 2006). 
 Elimination is the irreversible loss of drug from the site of measurement and 
can occur by two processes, excretion and metabolism (Rowland and Tozer, 1995). 
Excretion is the elimination of the drug in the unchanged form. Metabolism is the 
process by which a drug undergoes biotransformation normally with the objective of 
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reducing lipid solubility and increasing the possibility of further elimination. 
Metabolism is also normally referred as biotransformation and is the major 
mechanism for elimination of drugs from the body (Rowland and Tozer, 1995).  
The biotransformation process occurs mainly in the liver, being performed by 
Xenobiotic-Metabolizing Enzymes (XMEs), and is generally divided in Phase I and 
Phase II (Williams, 1959; Nebert and Dalton, 2006) (see section Drug Clearance and 
Infectious Diseases). Phase I reactions expose or introduce a functional group (e.g. –
OH, -COOH, -SH, -NH2) by oxidation, reduction or hydrolysis, normally creating more 
reactive products. Several enzymes are involved in this Phase I process, e.g. alcohol and 
aldehyde dehydrogenases, carboxyesterases, epoxide hydrolase and monooxygenases, 
being the Cytochromes P450 (CYP) the most important among them. Phase II reactions 
involves coupling of the drug or its polar metabolite with endogenous substrates such as 
glucuronic acid, sulfate, amino acids, acetyl groups, methyl groups and the tripeptide 
glutathione. Examples of enzymes involved in these reactions are the UDP-
glucuronosyl transferases (UGT), sulfotransferases (SULT), catechol-O-
methyltransferase (COMT), N-acetyltransferases (NAT), and glutathione S-transferases 
(GST). 
 Biotransformation is generally a detoxification process, but sometimes the 
metabolic product is more toxic than the initial compound. This enzymatic formation of 
more reactive metabolites is termed bioactivation. The bioactivation is important in the 
cases when the administered drug is an inactive prodrug that is converted into a 
pharmacologically active species.  
In addition to metabolizing enzymes, transport across biological membranes is 
important in drug disposition. In recent years, the xenobiotic-related transporters 
(XRTs) have been proposed and/or demonstrated to have a role in regulating the 
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absorption, distribution and excretion of many compounds (Eichelbaum et al., 2006; 
Nebert and Dalton, 2006). Nonpolar compounds can pass through the lipid bilayer and 
cross the membrane unassisted, but a membrane protein for transmembrane movement 
is usually necessary in the case of polar or charged compounds. The organic anion 
transporters (OATP, SLC21A) are an example of uptake carriers and the ATP-binding 
cassette (ABC) superfamily of membrane proteins are an example of efflux transporters. 
The transport proteins allow the conceptual definition of a Phase III of drug elimination 
(Ishikawa, 1992), where the products, normally of phase II (conjugates), are effluxed 
out of the cytosol. 
All these biotransformation processes are known to display inter-individual 
variability due to genetic polymorphisms that are associated to variable plasma levels of 
the drug. 
 
Pharmacodynamic Aspects 
 
 
Pharmacodynamics describes the effect of the drug – or its active metabolite – in 
the body though its binding to a receptor that mediate its effect. The pharmacological 
effect is dependent of different factors such as the drug dose, drug pharmacokinetics, 
and the receptor number at target organ or the other drugs interacting or competing for 
similar receptors (Perazella and Parikh, 2005).  
Drug target pharmacogenetics aims at the identification of the inherited basis for 
interindividual variability in drug response and toxicity, particularly when this 
variability is not explained by differences in drug concentration (variability in the 
pharmacokinetic process). Pharmacogenetic variants have been described in drug targets 
(e.g. the β2-adrenergic receptor, the angiotensin-converting enzyme or the 
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apolipoprotein E) and in their activation pathways that can influence drug response 
(Small et al., 2002; Evans and McLeod, 2003). 
 
Although many non-genetic factors influence drug response (Figure 1), genetics 
can theoretically account for 20–95 percent of variability in drug disposition and effects 
(Kalow et al., 1999). In the case of CYP3A4 it was estimated that more than 60% of the 
enzyme activity is under genetic control and that approximately 90% of the 
interindividual variability in hepatic CYP3A4 activity is genetically determined 
(Ozdemir et al., 2000).  
The study of variability began with a focus on drug metabolizing enzymes, but it 
has been extended to membrane transporters and also to the genes that code for drug 
targets (Meyer, 2004; Evans and McLeod, 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Non-genetic parameters influencing the variation in drug effect. 
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Malaria 
 
 Malaria is globally the most important parasitic disease, with transmission 
occurring throughout Africa, Oceania, Asia and Latin America. In 2005 the global 
incidence of malaria has been estimated at 350-500 million new clinical cases annually, 
which can cause up to 3 million deaths (Sachs, 2005). More than 90% of the malaria 
burden occurs in sub-Saharan Africa, where tuberculosis and HIV/AIDS are also 
important public health problems. In this continent, the children under the age of 5 years 
and pregnant women are the ones more affected with malaria (WHO and UNICEF, 
2005).  
The malaria epidemic situation worsened in the last decade with the spread of 
drug resistance in the parasite against the commonly used antimalarial therapies based 
on chloroquine (CQ) and sulfadoxine-pyrimethamine (SP). A new hope appeared with 
the introduction of artemisinins and combination therapy (White et al., 1999). 
 
 Malaria parasites are included in the protozoan subkingdom, class sporozoa. 
Four species of the Plasmodium genus are the canonically accepted as responsible for 
malaria in humans: P. falciparum, P. ovale, P. malariae and P. vivax. P. falciparum is 
essentially the sole agent responsible for the high mortality of the disease, a composite 
result of its virulence and drug resistance. The later is a major motor for the world trend 
of increased prevalence of this species over the other human infecting Plasmodia 
parasites. 
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Plasmodium life cycle 
 
 The life cycle in the four species of Plasmodium is relatively similar comprising 
two basic phases (Figure 2): an exogenous sexual phase (sporogony) in the female 
Anopheles mosquito and an endogenous asexual phase (schizogony) in human body. 
The asexual phase can be divided in a liver stage and an erythrocytic stage. When the 
mosquito infected with P. falciparum bites the human host it inoculates the sporozoites 
into the blood stream from where they migrate to the liver and invade the hepatocytes, a 
process that takes around 20 minutes. Inside the hepatocytes the sporozoite passes 
through different forms, being released back to the bloodstream as a merozoite (5 to 20 
days after liver invasion). The liver stage is asymptomatic with only a few liver cells 
being infected.  
The merozoites released invade the red blood cells (RBC), beginning the 
erythrocytic stage. In the erythrocyte the parasites become mature trophozoites that 
develop into new merozoites in 48 hours. Then they are released and can invade new 
RBC. Symptomatic disease begins when the asexual parasite multiplies in RBCs. To 
close the cycle, subpopulations of parasites develop into gametocytes and are ingested 
during a bite of a mosquito. The female and male gametocytes form a zygote in the 
insect’s midgut. The zygotes develop into motile sporozoites through asexual division 
in an oocyst attached to the intestinal wall of the mosquito. These sporozoites migrate to 
the salivary gland to continue the Plasmodium life cycle by infecting the next host 
during the mosquito feeding. 
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Figure 2 – Life cycle of P. falciparum and typical stages of action of antimalarial drugs 
(adapted from http://www–ermm.cbcu.cam.ac.uk). 
a – 8-Aminoquinolines (primaquine), folate inhibitors (proguanil) and atovaquone. b – 
Artemisinin drugs (artemisinin, dihydroartemisinin, artesunate, artemether), 4-
aminoquinolines (chloroquine, amodiaquine), quinoline methanols (quinine, 
mefloquine, halofantrine), folate inhibitors (proguanil, pyrimethamine, dapsone, 
sulfonamides) and atovaquone. c – Artemisinin drugs, Primaquine. (Baird, 2005; Patel 
and Kain, 2005; O’Neill et al., 2006) 
 
 
 
a 
b 
c 
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The Human Host – Genetic Resistance  
 
 In highly endemic areas the malaria risk is elevated in children and in pregnant 
women. This risk has been associated with the immune status of an individual. The 
innate immunity includes not only the cells of the immune system (e.g. natural killer 
cells, natural-killer-T cells or polymorphonuclear cells) but also host genetic factors. In 
malaria endemic areas certain diseases of red blood cells have been associated to a 
malaria protection, as the sickle cell trait, thalassemia, and enzyme deficiency or ABO 
blood groups.    
 The hemoglobin S gene geographical distribution is virtually identical to areas in 
the world in which malaria is (or has been) endemic (Ashley-Koch et al., 2000). Early 
epidemiological studies suggested that heterozygote carriers of the βs gene could 
acquire P. falciparum malaria but had a reduced relative risk of dying of the infection 
(Allison, 1954). This trait has been related to a premature removal of infected RBC 
(higher susceptibility to phagocytosis and lower ability to invade and multiply) and, 
more recently, it was suggested that the protection might involve immunological 
components, although the mechanism of protection was not yet fully resolved (Min-Oo 
and Gros, 2005; Williams, 2006).  
The thalassemias are disorders of hemoglobin production and they are divided in 
α- and β-thalassemia that are characterized by underproduction or deletion of the α- and 
the β-globin respectively (Weatherall and Clegg, 1982). Both alpha and beta 
thalassemias have been associated with decreased susceptibility to malaria infection 
(Flint et al., 1986). The protection afforded by thalassemia against malaria may be 
related to the inability of the parasite to invade or multiply, or to cytoadhere to 
endothelial cells (Udomsangpetch et al., 1993). 
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The blood group antigen polymorphisms can have an important role in malaria 
since the absence of certain glycophorin molecules on the surface of erythrocytes may 
affect parasite binding and invasion. P. falciparum binds specific sites on erythrocyte 
glycophorin (Pasvol, 1984), namely glycophorin A. Other red-cell-membrane-
associated proteins that have been implicated in malaria protection include complement 
receptors, knop-blood group and the ABO blood groups. Individuals with blood group 
O are relatively resistant to severe malaria caused by P. falciparum, since in individuals 
with this blood group the forming of rosettes is not so readily observed (Uneke, 2007).  
The enzyme glucose-6-phosphate dehydrogenase (G6PD) is part of the pentose 
phosphate pathway that is responsible for the production of NADPH that have a key 
role in supplying reducing equivalents in the infected RBCs. One function of NADPH is 
to be the reducing agent of GSSG to GSH and without this system perfectly working 
high levels of oxidative stress will be generated in the red blood cell.  
Deficiency of the activity of G6PD is extremely frequent in some regions of the 
world (e.g., tropical Africa, parts of the Middle East and Southeast Asia), areas where 
malaria is most prevalent. G6PD variants include G6PD A (present in frequencies of 15 
to 40%), G6PD B (60 to 80%) and G6PD A- (0 to 25%) (Ruwende and Hill, 1998). This 
last variant is responsible for the the lost of almost all enzyme activity since it is 
reduced to less than 15% (Ruwende and Hill, 1998). In addition to such epidemiological 
observations, in vitro studies have shown that the growth of P. falciparum is reduced in 
G6PD deficient red cells when compared with normal red cells (Miller et al., 1984; 
Roth et al., 1983). The mechanism behind this observation is not clear, but there is 
evidence that G6PD-deficient infected RBCs are phagocytosed more rapidly than those 
from normal individuals (Cappadoro et al., 1998). The G6PD-deficient cells lack the 
ability to resist sustained oxidative stress adequately and hence the free-radical-
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producing parasite is a challenge to such cells. This situation is thought to make the red 
cell more susceptible to phagocytosis. Also oxidative stress induced by the parasite, 
plus the normal red cell oxidative stress particularly unquenched by the enzyme 
deficiency, results in an environment in which normal parasite growth is limited (Senok 
et al., 1997).  
During last several million years the evolution in malaria lead to the selection of 
many genetic variants that confere some degree of protection against death from the 
disease, even sometimes it cost to maintain a highly deleterious allele like HbS. 
 
Antimalarial drugs 
 
 The first specific chemotherapies for the treatment of malaria, defined as 
“fevers” used extracts of the Chinchona tree (quinine), in the Andes, and Artemisia 
annua (artemisinin), in China. Quinine was for Centuries the only antimalarial drug 
available in the Western World. Through pressure of the global conflicts in the XX 
century, significant efforts for the development of synthetic antimalarials were applied. 
Chloroquine was one of the drugs that resulted from these efforts. It proved to be a safe 
drug with few toxic effects and was used by the WHO in the program for global malaria 
eradication. In the late 1950’s resistance to CQ was almost simultaneously reported in 
Thailand, Colombia and Venezuela (Peters, 1970). From these first foci of CQ 
resistance a growing number of countries had to face this problem and today CQ 
resistance had spread to all the regions where malaria is endemic (Wongsrichanalai et 
al., 2002). Only some regions in Central America, North of the Panama Canal and on 
the island of Hispaniola, chloroquine-resistant P. falciparum malaria have not been 
consistely documented (WHO, 2005). 
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The major antimalarial drugs in use can be separated in 4-aminoquinolines, 8-
aminoquinolines, aryl aminoalcohols (or quinoline methanols), sesquiterpene 
endoperoxides, antifolates and antibiotics. The 4-aminoquinolines includes chloroquine 
and amodiaquine and the 8-aminoquinolines the animalarial primaquine. The aryl 
aminoalcohols includes mefloquine, lumefantrine, halofantrine and quinine, and the 
sesquiterpene endoperoxides the artemisinin-type compounds (e.g. dihydroartemisinin, 
artesunate, artemether and arteether). Finally, the antifolates includes the Type-I 
antifolates (e.g. sulfones and sulfonamides) and the Type-II antifolates (e.g. 
pyrimethamine and proguanil) and the antibiotics the tetracycline, doxycycline and 
clindamycin. The different known antimalarials have diverse points of action in the P. 
falciparum life cycle (Figure 2). 
Some pharmacological properties of the main antimalarials (Figure 3) in use for 
the treatment of P. falciparum malaria are shown in Table 1. 
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Figure 3 – Structures of the main antimalarial drugs used in first-line treatments 
(structures from www.genome.jp/kegg/, Kyoto Encyclopedia of Genes and Genomes). 
      
                         
                     Chloroquine                                                Amodiaquine                             
 
                       
          
          Mefloquine                                Quinine                                Lumefantrine    
 
                                            
       
                Pyrimethamine                                                  Sulfadoxine                             
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Table 1 – Pharmacological properties of the antimalarials in widespread use*. 
 Chloroquine Amodiaquine Quinine Mefloquine Sulfadoxine Pyrimethamine Lumefantrine 
Artemisinin 
drugs 
Action  
Interferes with 
parasite haem 
detoxification 
Interferes with 
parasite haem 
detoxification 
(hypothesis) 
Inhibits the 
ingestion of host 
cell haemoglobin 
(hypothesis) 
Inhibits the 
ingestion of host 
cell haemoglobin 
(hypothesis) 
DHPS inhibitor DHFR inhibitor  
Interferes with 
parasite haem 
detoxification 
(hypothesis) 
Inhibits SERCA 
(hypothesis) 
tmax (hrs)** 1 to 3 0.6 to 1.3 1 to 4 6 to 24 2 to 6 2 to 12 10 1 to 3 
t1/2β  8 - 58 days 2 - 10 hrs 11 - 18 hrs 14 to 22 days 4 to 9 days 4 to 6 days 33 hrs - 6 days 45 min to 4 hrs 
Protein 
binding 
50 to ~60% > 90% 80 to 90% ~98% 90 to 95% 80 to 90% > 99% ~50 to > 90% 
Metabolism 
*** 
CYP2C8, CYP3As, 
CYP2D6**** 
CYP2C8 
CYP3As, 
CYP2C19**** 
CYP3A4 Acetylation ? CYP3A4 
CYP2A6, 
CYP2B6, 
CYP3As, 
Glucuronidation 
Toxicity  
Skin eruptions, 
gastrointestinal 
disturbs, central 
nervous system 
toxicity 
No evidence for 
serious toxicity 
in AQ therapy 
Gastrointestinal 
disturbs, 
cardiovascular and 
haematological 
effects  
Nausea, vomiting, 
anorexia, loss of 
balance, 
cardiovascular 
effects 
Allergic 
reactions, 
anorexia, 
Stevens-Johnson 
syndrome 
Skin rashes, 
gastrointestinal 
disturbs, 
haematological 
effects 
 
Ototoxicity  
Neurotoxicity 
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* Data in the table is from Bray et al., 2006; Ezzet et al., 1998; Famin and Ginsburg, 
2002; Foley and Tilley, 1997; Giao and de Vries, 2001; Grace et al., 1998; Ilett et al., 
2002; Li et al., 2002; Li et al., 2003; Meyer and Zanger, 1997; Projean et al., 2003; 
Rodriguez-Antona et al., 2005; Schmuck et al., 2002; Svensson and Ashton, 1999; 
Toovey, 2006a; Wanwimolruk et al., 1991; Winstanley et al., 1987; Winstanley and 
Ward, 2006; Zhao et al., 1996. 
 
** Peak plasma concentrations. 
 
*** For further information see section Drug Clearance and Infectious Diseases.  
 
**** These enzymes are involved to a minor extent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  16
Quinolines 
 
Quinine was the first antimalarial available in the Western World. It is still used 
today to treat the more severe cases of the disease and also as the second line treatment 
in some countries (www.who.int/malaria/treatmentpolicies.htm). The 4-aminoquinoline 
antimalarials (CQ and AQ) and related aryl aminoalcohols quinolines (mefloquine, 
lumefantrine and halofantrine) are, in general, synthetic derivatives of the quinine 
structure.  
Chloroquine (CQ) was the global mainstay for the treatment of uncomplicated 
malaria for decades due to its safety, efficacy and low cost. This changed when P. 
falciparum CQ resistance emerged and spread (Rathore et al., 2005). 
Amodiaquine (AQ) is an effective antimalarial that emerged as an option for 
the treatment of CQ resistant malaria in the low-resource settings (Olliaro and Mussano, 
2003).  
Mefloquine and lumefantrine (previously called benflumetol) are synthetic aryl 
aminoalcohols quinolines presently in wide use in artemisinin-based combination 
therapy (ACT). Lumefantrine is only available co-formulated with artemether, under the 
brand names Coartem® (Developing World) and Riamet® (Industrialised World) 
(Novartis AG, Basel, Switzerland). Coartem® and AS + AQ represent the main ACTs in 
use in Africa, while mefloquine in combination with artesunate is mainly used in South 
East Asia malaria settings (Nosten and Brasseur, 2002). AS + AQ is now available in a 
fixed combination under the name Artesunate-Amodiaquine Winthrop® (ASAQ) for 
the public markets, and under the brand name Coarsucam® in the private markets 
(Sanifi-Aventis, Paris, France and DNDi). 
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Antifolates 
 
 The antifolates are an important group of antimalarials that exploit the ability of 
malaria parasites to synthesise folate de novo, which differs from the human host where 
the folates come from dietary intake. The antifolate drugs consist of dihydrofolate 
reductase enzyme (DHFR) inhibitors (such as pyrimethamine) and sulfonamides that 
inhibit the dihydroopteroate synthetase enzyme (DHPS). The application of antifolates 
as antimalarial drugs was enhanced by the discovery of synergism in drug combinations 
involving both classes of inhibitors that block nucleic acids synthesis in the parasite 
(Wang et al., 2004). 
  
 
Artemisinin derivatives 
 
Another group of antimalarial drugs includes artemisinin (ART) and its 
derivatives (Figure 3). This family of drugs is characterized by rapid parasite clearance 
times and low toxicity. The artemisinin drugs have the highest Parasite Reduction 
Ratio (PRR), defined as the ratio between parasite count before treatment and 48 hours 
later (one parasite cycle). For ART this value is comprised between 103 and 105 
compared with 10 to 102 described for mefloquine or quinine (White, 1997). This higher 
PRR of ART leads to a rapid clinical and parasitological cure that is highly effective 
against multidrug resistant parasites.  
Artemisinin drugs have the broadest parasite stage specificity, being effective in 
most intraerythrocytic cycle stages, although with distinctive stage specific activities 
(Ter Kuile et al., 1993; Skinner et al., 1996). Artemisinin was demonstrated to be 
rapidly effective against both rings and schizonts (100% growth inhibition within 4 to 
6h) but in the case of trophozoites it takes 10h to achive 60% growth inhibition (Skinner 
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et al., 1996).  In the case of artemether the inhibitory effect is more gradual (70% 
growth inhibition within 8 to 10h), but, in contrast, dihydroartemisinin was described to 
be highly effective against all stages of the parasites (100% growth inhibition within 
24h) (Skinner et al., 1996). The quinghaosu drugs are also effective in reducing 
gametocyte carrier rates, and as a consequence, transmission of malaria (Chen et al., 
1994; Price et al., 1996).  
It was shown that after repeated doses of ART, the drug first-pass elimination 
effect was increased significantly (Ashton et al., 1998). This effect is possibly 
associated to the fact that ART is an effective ligand of the nuclear receptors PXR 
(pregnane X receptor) and CAR (constitutive androstane receptor) (Burk et al., 2005; 
Simonsson et al., 2006) (see section Drug Clearance and Infectious Diseases – 
Pregnane X Receptor). These nuclear receptors can induce a significant number of 
detoxification enzymes and transporters, including the enzymes involved in the 
metabolism of ART and its semi-synthetic derivatives (Table 1). This activation 
capacity constitutes a potential source of drug-drug interactions, when in the context of 
large scale combination therapy. 
 
Amodiaquine, and its main metabolite desethylamodiaquine, are two main 
objects of study in this thesis constituting an important link between most parts of the 
work herein presented. Hence, more detail will be referred concerning these 
compounds.  
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Amodiaquine 
 
 
 Amodiaquine (AQ) is a 4-aminoquinoline, structurally similar to CQ (Figure 3), 
with a suggested similar mode of action against P. falciparum, but more active against 
most chloroquine-resistant parasites (Foley and Tilley, 1998). This drug was associated 
with rare but severe events in prophylaxis regimens. These events include 
agranulocytosis and hepatotoxicity (Meshnick and Alker, 2005). Severe adverse events 
have not been documented in current treatment therapies (Olliaro and Mussano, 2003). 
In line with the recent global strategy for malaria control, the present WHO 
guidelines recommend the use of AQ as a partner in combination therapy. In ACT the 
partner of AQ is AS, a combination adopted in different countries as the first line 
treatment (www.who.int/malaria/treatmentpolicies.htm). In non-ACT AQ is typically 
combined with SP, a strategy in use by the Malaria Control Programmes of Papua New 
Guinea and Colombia (www.who.int/malaria/treatmentpolicies.htm; Genton et al., 
2005; Blair et al., 2006). 
Amodiaquine pharmacokinetics data is limited, particularly in which concerns 
the paediatric population, the main target group for this antimalarial therapeutic. The 
studies developed in healthy adults and in children from Papua New Guinea showed 
that AQ is readily absorbed (tmax ranging from 0.6 to 1.3 hours in adult health subjects) 
from the gastro-intestinal tract, being rapidly and extensively metabolized in the liver to 
the main metabolite, N-desethylamodiaquine (DEAQ) (Winstanley et al., 1987; 
Hombhanje et al., 2005). Minor metabolites were identified in vivo and in vitro in 1995 
by Jewell and collaborators and include 2-hydroxyl-desethylamodiaquine and N-
bisdesethylamodiaquine (Jewell et al., 1995). These metabolites were not observed in a 
posterior in vitro study using human liver microsomes and recombinant Cytochromes 
P450 (Li et al., 2002), but in a in vivo study N-bisdesethylamodiaquine was identified in 
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a blood sample (Minzi et al., 2003). A recent study has analysed the in vitro metabolism 
of AQ using recombinant CYP2C8 proteins and also did not identify other metabolites 
besides DEAQ (Parikh et al., 2007). The differences observed in the different studies 
may be the result of different in vitro or in vivo approaches. 
DEAQ constitutes the main compound responsible for the long term effect of 
AQ therapy (Winstanley et al., 1987; Hombhanje et al., 2005), with AQ being rapid and 
extensive metabolized into DEAQ (Li et al., 2002).  
AQ is primarily eliminated through biotransformation and has been suggested to 
be excreted in bile since the percentage of the drug recovered in urine is very small 
(Winstanley et al., 1987). The elimination pathways of DEAQ have not been clearly 
elucidated, but this metabolite was suggested to be eliminated by renal excretion (Giao 
and de Vries, 2001).  
AQ is eliminated in humans via extensive first-pass biotransformation to DEAQ 
resulting from the hepatic activity of CYP2C8 (Li et al., 2002). Two other enzymes, 
CYP1A1 and CYP1B1, were shown to metabolise AQ in vitro, and may contribute to 
the elimination of AQ at an extrahepatic level (Li et al., 2002). 
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Resistance to antimalarial drugs 
 
 Antimalarial drug resistance is defined by the WHO as “the ability of a parasite 
strain to survive and/or multiply despite the proper administration and absorption of a 
medicine given in doses equal to or higher than those usually recommended” (WHO, 
2005).  
Resistance has been reported for all antimalarial classes of drugs (for artemisin 
drugs only in vitro resistance was described (Jambou et al., 2005; Afonso et al., 2006)). 
The molecular basis and mechanisms of action behind these phenotypes are still not 
totally understood (Krishna et al., 2006; White, 2004), although it might partially 
include mutations in the SERCA protein coded by the PfATP6 gene (Eckstein-Ludwig 
et al., 2003). 
 Numerous factors can be involved in the development of resistance and they can 
go from socio-economic factors to pharmacokinetics or parasite biology. One of the 
most important is subtherapeutic drug pressure that occurs when a sufficient number of 
human hosts carry residual drug levels to which infecting malaria parasites are exposed 
(Hastings and Watkins, 2005). This exposure to subtherapeutic drug levels result in a 
higher tolerance in the parasite population.   
The quantity of drug that reaches the target (parasite’s metabolism and 
detoxification of haemoglobin, antifolate synthesis, mitochondria or the 
sarco/endoplasmic reticulum Ca2+-ATPase) in the parasite is determined by the human 
host pharmacokinetics, which is in turn influenced by the properties of each drug 
(Daily, 2006). Artemisinin derivatives are eliminated very fast (tipically t1/2 < 1h) and 
are in general never presented to parasites at subtherapeutic drug concentrations for 
sufficient time to allow the selection process to occur. The same does not happen with 
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drugs that are slowly eliminated (e.g. mefloquine, chloroquine). In this case the 
parasites are exposed to low concentrations of drug for enough time to complete several 
intraerythrocyte cycles and this leads to the selection of resistant parasites. If 
gametocytes are allowed to be produced this selection can be further transmitted. 
Pharmacogenetic diversity can influence individual drug pharmacokinetics 
through variability in XMEs, drug transporters and the nuclear receptors that control the 
expression of the former, affecting the metabolism and elimination of antimalarial 
drugs, and leading to variable drug levels in circulation. The different enzymes involved 
in the metabolism of antimalarials are possible sources of variability in the treatment 
outcome. 
 In summary, different pharmacokinetic characteristics can lead to different 
periods of sub-therapeutic doses of antimalarials, hypothetically leading to the 
aforementioned drug resistance parasite selection.  
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Combination therapy 
 
 
 Monotherapy is no longer an effective option against malaria in endemic 
regions, a consequence of the development of P. falciparum resistance against the 
mainstay antimalarial drugs. Mirroring the development of chemotherapy in other major 
infectious diseases (e.g. TB, AIDS) combination therapy represents the present effort to 
delay the spread of drug resistance and to maintain high efficacy of current drug 
regimens. Among the several possible and available combinations, artemisinin-based 
combination therapy (ACT) has been used in South-East Asia for a decade now with 
considerable success. ACT combines artemisinin compounds that produce a rapid 
clearance of parasitaemia and fever, with slowly eliminated antimalarial drugs like 
amodiaquine or lumefantrine (Figure 4).  
The success obtained in Asia led WHO to promote the massive introduction of 
ACTs in most countries affected with malaria, with particularly emphasis in sub-
Saharan Africa (Mutabingwa, 2005). However, the long term success of ACT observed 
in South-East Asia, an area with low transmission of malaria, is not clear to be repeated 
in most countries in Africa, with high transmission rates. This difference is related to 
the fact that in low transmission areas the risk of re-infection is low; therefore there is a 
reduced probability of new parasites being submitted only to the presence of the long 
life partner (after the fast elimination of ART). But in areas where the transmission is 
high the patients are submitted to frequent re-infections, with the new parasites facing 
only the long life partner. This can lead to the selection of parasites with growing drug 
tolerances and, in the future, to the development of in vivo resistance to ACT (Sisowath 
et al., 2005; Hastings and Ward, 2005).    
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Figure 4 – The pharmacodynamic concept of artemisinin combination therapy (ACT). 
Reducing the parasite biomass with the high PRR drug (artesunate) protects the partner 
drug (amodiaquine), only obliged to face with a number of parasites several orders of 
magnitude smaller (adapted from Gil and Gil-Berglund, 2007).  
 
Presently the use of combination therapies involves some disadvantages: (1) 
treatment courses with higher costs as compared with common monotherapy regimens 
(Wiseman et al., 2006); (2) The possibility of inappropriate use of artemisinin 
derivatives if the ACT is not available in a fixed formulation – ART use as  
monotherapy can lead to high recrudescence rates and possibly to the rise of resistance 
(Jambou et al., 2005); (3) the lack of information about safety (e.g. the embryotoxicity 
and potentially teratogenic effect associated with artemisinin drugs in animals is 
unknown in humans, but there are some evidence from clinical of neurotoxicity 
associated with these compounds), associated to a possible increase in the risk of 
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adverse effects and/or drug-drug interactions (Mutabingwa, 2005; Toovey et al., 
2006b). 
The combination therapies adopted around the world as first-line treatment 
against P. falciparum malaria are presented in Figure 5.  
 
 
 
Figure 5 – Distribution of artemisinin combination therapies officially adopted as first-
line treatment in malaria endemic countries (data from www.who.int/malaria/ 
treatmentpolicies.htm). Blue – Artesunate + Amodiaquine (Artesunate-Amodiaquine 
Winthrop® or Coarsucam®); Black – Artemether + Lumefantrine (Coartem®); Green – 
Artesunate + SP; Red – Artesunate + Mefloquine; Grey - Dihydroartemisinin + 
piperaquine (Artekin®). 
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Drug Clearance and Infectious Diseases 
 
In most tropical regions infectious diseases represent the major burden for the 
national public health systems. The major infectious diseases were responsible for 14.7 
million deaths in 2001 (http://www.who.int). Among them malaria, HIV/AIDS and 
tuberculosis (TB) – the Big Three (Hotez et al., 2006) – account for the biggest burden: 
an average of two million people with malaria die each year, three million people died 
from AIDS while four million have active tuberculosis at any time (Fauci, 2005; WHO, 
2004).  
Differences on ethnicity may have a notable impact on drug clearance, thus 
affecting the safety and efficacy of the dosing regimens. Drug clearance might be 
further affected in the context of tropical regions due to drug-drug interactions 
associated to the multiple drug therapy for concurrent infectious diseases. 
Scarce data is available on the pharmacogenetic characteristics of populations 
concerning the genes involved in the elimination of the drugs currently used for the 
treatment of the major infectious diseases. The evaluation of pharmacogenetic 
differences would be a useful tool in the definition of average recommended doses, so 
that the starting dose in one population would correspond to the mean value in the main 
affected ethnic group. To note that ethnic differences in drug exposure are related not 
only to biological factors, but also social, cultural or economical aspects of a region. 
This includes local medical practice and compliance with prescribed medications, as 
well as diet, and particularly exposure to xenobiotics e.g. tobacco, alcohol (ethanol), 
industrial pollutants.  
The metabolism of several antimalarial drugs has been related to different 
cytochrome P450s including CYP2B6 (artemisinin derivatives), CYP2C8 (CQ, AQ), 
CYP2D6 (CQ), CYP3A4 (CQ, LUM, quinine and artemisinin derivatives) or CYP3A5 
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(quinine) (Li et al., 2003; Simonsson et al., 2003; Svensson and Ashton, 1999; Grace et 
al., 1998; Rodriguez-Antona et al., 2005). Drug transporters are associated to 
antimalarials metabolism and, an example, is the in vitro interaction of mefloquine with 
MRP1 (ABCC1) and MRP4 (ABCC4) (Wu et al., 2005). ABC transporter 
ABCB1/MDR1 (P-glycoprotein, Pgp) is involved in the transport of different 
antimalarials and this issue will be developed in section Drug Transporters – 
Multidrug Resistance 1 gene. Completing this picture, the nuclear receptors PXR and 
CAR, were recently demonstrated to be activated in vitro by artemisinin derivatives 
(Burk et al., 2005; Simonsson et al., 2006), as this protein is able to influence the 
transcription activity of all the previously mentioned loci. 
The metabolism of several anti-HIV/AIDS drugs is also mainly performed by 
cytochrome P450s, including protease inhibitors (normally CYP3A4; nelfinavir, 
CYP2C19) and non-nucleoside transcriptase inhibitors (CYP3A4 and CYP2B6) (Khoo 
et al., 2005). The ABC proteins P-glycoprotein (Kim, 2003) and MRP2 (ABCC2) 
(Gutmann et al., 1999; Huisman et al., 2002) have also been proposed as transporting 
HIV protease inhibitor drugs. 
 
This thesis is particularly focused on the pharmacogenetics of the cytochrome 
P450 superfamily, responsible for the highest contribution for variability among XMEs. 
Besides that, the pharmacogenetics of two Phase II enzymes, N-acetyltransferase 2 
(NAT2) and Glutathione S-Transferase (GST), as well as an ABC transporter 
(ABCB1/MDR1), and the nuclear receptor pregnane X receptor was also investigated. 
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Cytochrome P450 (CYP) 
 
 The superfamily of CYPs, involved in the phase I metabolism of most drugs, has 
the highest impact among XMEs. In Homo sapiens the CYP superfamily includes 107 
members, 57 of them known to code for active enzymes 
(http://drnelson.utmem.edu/CytochromeP450.html).  Most CYP proteins are localized in 
the liver, contributing for the importance of this organ in xenobiotic metabolism. Extra-
hepatic localizations are particularly important concerning the gut and the kidney with 
respect to orally administered and renally cleared drugs. The CYP enzymes are 
classified in families (enzymes sharing ≥ 40% amino acid sequences) and subfamilies 
(enzymes sharing ≥ 55% amino acid sequence). The first Arabic number indicates the 
family (CYP1), the letter indicates the subfamily (CYP1A) and another Arabic number 
corresponds to the individual gene (CYP1A1). The gene name is written in italic 
(CYP1A1) and the mRNA and protein in regular capital letters (CYP1A1). 
The major human CYP enzymes responsible for catalyzing drug 
biotransformation are members of families CYP1, CYP2 and CYP3. Two subfamilies 
are particularly abundant in human liver microsomes, CYP2C and CYP3A, accounting 
for approximately 20% and 30%, respectively, of total CYP content (Shimada et al., 
1994). Genetic polymorphisms with functional consequences have been described in 
most CYP families (http://www.cypalleles.ki.se). 
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In the studies included in this thesis we have primarily focused in: 
a) CYP2C8 because of its importance in the hepatic metabolism of AQ (Li et al., 
2002); 
b) CYP1A1 and CYP1B1 involved in the in vitro biotransformation of AQ and with 
a possible role in the extrahepatic metabolism (Li et al., 2002); 
c) CYP3A4 described to be involved in the metabolism of LUM, quinine and ART 
derivatives and CYP3A5 for quinine (Li et al., 2002; Lefevre et al., 2000; Grace et 
al., 1998; Rodriguez-Antona et al., 2005).  
 
CYP1A1 
CYP1A subfamily includes two members, CYP1A1 and CYP1A2. The CYP1A1 
and CYP1A2 loci are located at chromosome 15q22-qter (CYP1A1 reading towards the 
telomere and CYP1A2 reading towards the centromere) and the two genes are separated 
by 23 kilobases (Kb) (Corchero et al., 2001). CYP1A1 is an important enzyme in extra-
hepatic tissues and is mainly expressed in human heart, lung, prostate, thymus, intestine, 
placenta, and lymphocytes (Ding and Kaminsky, 2003; Shimada et al., 1994; 
Choudhary et al., 2005). Its expression is highly inducible by several xenobiotics (e.g. 
polycyclic aromatic hydrocarbons), via the AhR/ARNT pathway (Ma, 2001). The 
enzyme’s endogenous substrate is unknown but CYP1A1 was described to be involved 
in the in vitro metabolism of many drugs, including drugs important in the context of 
tropical medicine such as amodiaquine, quinine, and chloroquine, although only as a 
minor contributor  (Li et al., 2002; Li et al., 2003).  
CYP1A1 is a polymorphic gene and fourteen allelic variants have been 
determined (http://www.cypalleles.ki.se) (Figure 6). The protein coding region includes 
six of seven exons. One of the major SNPs present in this region is the 2455A>G 
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substitution in exon 7, leading to the amino acid change Ile462Val located near the 
heme binding region (Hayashi et al., 1991). This alteration is present in both 
CYP1A1*2B and *2C alleles and its influence over the enzyme activity is still under 
discussion (Cosma et al., 1993; Crofts et al., 1994; Persson et al., 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Structure of the CYP1A1 gene (data from http://www.ensembl.org/). The 
ATG start codon is close to the 5’ end of exon 2 producing a protein of 512 amino 
acids. Arrows indicate the location of the nucleotide changes present in the coding 
region (data from http://www.cypalleles.ki.se). 
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CYP1B1 
The CYP1B1 gene, located in chromosome 2, is composed of three exons with 
the open reading frame (ORF) starting on exon two (Figure 7) (Tang et al., 1996). The 
coded enzyme is mainly of extrahepatic expression, and is present in a large range of 
tissues, including kidney, prostate, mammary gland, and ovary (Sutter et al., 1994; 
Shimada et al., 1996; Tang et al., 1999). Like the other members of CYP1 family, the 
induction of CYP1B1 is regulated by the AhR/ARNT pathway (Sutter et al., 1994). 
This enzyme is involved in the biotransformation of estradiol, tegafur, docetaxel, 
mitoxantrone, flutamide and amodiaquine (in vitro and to a minor extent) (Rodriguez-
Antona and Ingelman-Sundberg, 2006; Michael and Doherty, 2005; Li et al., 2003).   
Different physiological roles have been reported for CYP1B1, including the 
participation in the metabolism of endogenous substrates such as the steroid 17β-
estradiol and steroid hormones estrone, testosterone and progesterone (Shimada et al., 
1999). Another physiological function of CYP1B1 is in ocular development and 
differentiation in humans, supported by the identification of rare mutations in the gene 
in patients with primary congenital glaucoma (Stoilov et al., 1997; Stoilov et al., 1998; 
Kakiuchi et al., 1999). 
Twenty-two alleles were described in CYP1B1 (http://www.cypalleles.ki.se).  
Six alleles (CYP1B1*2 to CYP1B1*7) are the result of different combinations of five 
nonsynonymous SNPs that give origin to the amino acid substitutions R48G, A119S, 
L432V, A443G and N453S (Stoilov et al., 1998; Bailey et al., 1998). The effect of these 
alleles is not well established, but CYP1B1*6 and CYP1B1*7 seem to be associated 
with a highly significant decrease in turnover numbers for both 2- and 4-hydroxylation 
of 17β-estradiol (Aklillu et al., 2002). 
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Figure 7 – The CYP1B1 gene has 12Kb and contains three exons (data from 
http://www.ensembl.org/). The translation begins close to the 5’ end of the second exon 
producing a protein of 543 amino acids. The nucleotide changes in the coding region are 
indicated by arrows (data from http://www.cypalleles.ki.se). For simplicity, the large 
deletions that give origin to the alleles CYP1B1*16, CYP1B1*17, CYP1B1*22 and 
CYP1B1*26 are not represented.   
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CYP2C8 
The human CYP2C8 gene (Figure 8) is one of the four members in the CYP2C 
cluster (Cent–RBP4–CYP2C18–CYP2C19–CYP2C9–CYP2C8-Tel) at chromosome 10 
(Gray et al., 1995). The CYP2C8 enzyme is mainly expressed in the liver, accounting 
for 7% of the total microsomal CYP content of this organ, but also in various extra-
hepatic tissues (Shimada et al., 1994; Klose et al., 1999). It plays an important role in 
the metabolism of several therapeutic drugs including the anticancer paclitaxel, the anti-
arrhythmic amiodarone, the calcium channel blocker verapamil or the antidiabetic 
troglitazone (Rahman et al., 1994; Borlak et al., 2003; Tracy et al., 1999; Yamazaki et 
al., 1999). Particularly important in the context of this thesis is the main role of 
CYP2C8 in the metabolism of the antimalarial amodiaquine (Li et al., 2002).   
This enzyme is also involved in the metabolism of several non-steroidal anti-
inflammatory drugs (NSAIDs), such as diclofenac, as well in the metabolism of the 
cholesterol lowering drug cerivastatin (for a more complete list of substrates see Totah 
and Rettie, 2005). Besides the exogenous substrates, CYP2C8 has an endogenous role 
since it has been described to be involved in the biosynthesis of endogenous 
vasoregulating factors from their arachidonic acid precursor (Dai et al., 2001). 
The wide range of substrates presented for CYP2C8 may be a consequence of a 
large active site (1438 Å3), akin to the observed in CYP3A4 and significantly larger 
than the active site of the other members of CYP2C subfamily (Schoch et al., 2004). 
Although CYP2C8 shares 70% sequence homology with CYP2C9 and 25% with 
CYP3A4, this enzyme shares many more substrates with CYP3A4. The structure of 
CYP2C8 was determined by X-ray diffraction as a symmetric dimmer in the presence of 
two molecules of palmitate (Schoch et al., 2004). No additional structures of CYP2C8 
in a complex with other substrates were determined and substrate docking is the only 
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available information besides the crystal structure (Li et al., 2002; Lewis, 2002; Melet 
et al., 2004).   
 
In total only eleven alleles were described for CYP2C8 
(http://www.cypalleles.ki.se) and this reflects a relatively low number of non-
synonymous SNPs documented for CYP2C8 (reviewed by Gil and Gil Berglund, 2007). 
The main polymorphisms, CYP2C8*2 (harbouring 805 A>T), CYP2C8*3 (carrying both 
416 G>A and 1196 A>G) and CYP2C8*4 (792 C>G), lead to the amino acid changes 
I269F, R139K, K399R and I264M, respectively. These variants have been documented 
to be associated with altered in vitro enzyme activity towards the probe drug paclitaxel 
(Dai et al., 2001; Bahadur et al., 2002). Specifically, CYP2C8*2 allele was observed to 
cause an increase on the Km for paclitaxel transformation while CYP2C8*3 was 
documented to be associated with an enzyme activity significantly lower for paclitaxel 
hydroxylation and a decrease in the metabolism of arachidonic acid (Dai et al., 2001). 
Conversely, another study has analysed CYP2C8*3 and CYP2C8*4 activities in human 
liver microsomes having shown small differences in paclitaxel hydroxylation for both 
alleles (Bahadur et al., 2002). A recent study had determined the kinetic parameters of 
DEAQ formation by CYP2C8 “wild-type” and main variants (Parikh et al., 2007). The 
CYP2C8*2 allele is reported to present a lower Vmax and intrinsic clearance, and a 
higher Km when compared with CYP2C8*1. For CYP2C8*3 allele the authors report 
that the decrease of AQ desethylase activity is profound, precluding the determination 
of the kinetic parameters.  
 The prevalence of the three major alleles has been suggested to differ 
significantly between ethnic groups (Dai et al., 2001; Bahadur et al., 2002; Nakajima et 
al., 2003). 
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Figure 8 – CYP2C8 gene structure where the nucleotide changes present in the coding region of the gene are represented (http://www.cypalleles.ki.se/). 
The 3D structure of CYP2C8 protein was obtained from PDB (PDB access number 1PQ2). CYP2C8 was crystallized as a symmetric dimer (Schoch et 
al., 2004).  
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CYP3A4 
 
The CYP3A subfamily includes four genes localized in a cluster at chromosome 
7 (Cent–CYP3A43–CYP3A4–CYP3A7–CYP3A5–Tel). CYP3A4 is one of the 
quantitatively most important drug metabolising enzymes involved in both hepatic and 
intestinal metabolism of drugs. CYP3A4 metabolizes about 50% of all prescribed drugs, 
including taxanes, vinca-alkaloids, irinotecan, etoposide, antimalarials and antiretroviral 
drugs (Guengerich, 1999; Li et al., 2003; http://medicine.iupui.edu/flockhart/). The 
large list of CY3A4 substrates is consistent with a large active site that goes from ~950 
Å3 in a ligand-free structure to 1650 Å3 with ketoconazole and 2000 Å3 in the presence 
of erythromycin (Ekroos and Sjogren, 2006). 
 
The CYP3A4 enzyme was also described to be involved in the metabolism of 
endogenous compounds, contributing in a minor extent to the bile acid biosynthesis in 
humans since it is involved in the conversion of cholesterol to 4β-hydroxycholesterol 
(Bodin et al., 2001). It is also responsible for carrying out the 25-hydroxylation of the 
bile acid intermediate 5β-cholestane-3α, 7α, 12α-triol (Furster and Wikvall, 1999; 
Honda et al., 2001) and metabolizes different steroids such as testosterone, 
progesterone, pregnenolone, cortisol and estradiol (Guengerich et al., 1986; Ged et al., 
1989; Niwa et al., 1998; Kerlan et al., 1992; Miller et al., 2004). 
 
CYP3A4 exhibits an important individual variability, which cannot, at present, 
be satisfactorily attributed to genetic polymorphism. This is also observed in other CYP 
enzymes, as is the case of CYP1A2 where a recent in vivo study could not found an 
association between the genotype and the phenotype that explains the interindividual 
differences (Jiang et al., 2006). Among the SNPs identified to date, some are reported to 
affect function, but are not present at a high frequency in any ethnic group studied, 
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being therefore not likely to have major pharmacological consequences. The metabolic 
variability may rather be due to environmental factors and/or to polymorphisms in 
factors regulating gene transcription. 
More than thirty allelic variants (http://www.cypalleles.ki.se) have been 
identified in the CYP3A4 gene, resulting from combinations of SNPs located in the 
ORF, promoter and intronic regions (Figure 9). Most of them seem not to have 
significant consequences for gene expression or protein activity. An exception in this 
context is the relatively common −392A>G (CYP3A4*1B) SNP, notably frequent in 
populations of African origin (Ball et al., 1999; Rodriguez-Antona et al., 2005). Of 
interest in the frame of this thesis, it was recently demonstrated that CYP3A4*1B, 
previously suggested to be a transcriptionally less active allele (Rebbeck et al., 1998), is 
associated to a reduced in vivo metabolism of quinine in Tanzanians (Rodriguez-Antona 
et al., 2005).  
The initial search for variants with functional significance led to the report of 
two non-synonimous SNPs in the coding region of CYP3A4, leading to the amino acid 
changes S222P (CYP3A4*2) and M445T (CYP3A4*3) (Sata et al., 2000). CYP3A4*2 
was associated with lower intrinsic clearance for nifedipine when compared with the 
reference allele (Sata et al., 2000). 
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Figure 9 – The CYP3A4 gene is constituted by 13 exons in 26.5 Kb. The data about the size of the introns and exons is from Gellner et al., 2001. Only 
the SNPs present in the coding region of the gene are represented (http://www.cypalleles.ki.se/). The 3D structure of CYP3A4 protein was obtained 
from PDB (PDB access number 1TQN). 
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CYP3A5 
The CYP3A5 gene is composed of 13 exons and an ORF that originates a protein 
with 502 amino acids (Figure 10).  
CYP3A5 substrates are less well documented as compared with CYP3A4. 
However, it has been shown that CYP3A5 plays a major role in the metabolism of a 
wide variety of substrates (Kuehl et al., 2001), such as HIV-1 protease inhibitors 
(Koudriakova et al., 1998), and the antimalarial quinine (Rodriguez-Antona et al., 
2005). The CYP3A5 protein is expressed in liver but also abundantly in different extra-
hepatic locations, such as lung (Kivisto et al., 1996), kidney (Schuetz et al., 1992; 
Haehner et al., 1996), breast (Huang et al., 1996) and leukocytes (Janardan et al., 1996). 
The contribution of CYP3A5 in hepatic CYP3A drug metabolism displays a 
high variation - from 6 to 99%. However, this enzyme can represent at least 50% of the 
total CYP3A hepatic content in subjects where it is expressed (Wrighton et al., 2000; 
Kuehl et al., 2001). Although several variants have been described for CYP3A5 
(http://www.cypalleles.ki.se), the documented polymorphic expression of CYP3A5 is 
mainly due to a polymorphism (6986 A>G) within intron 3 (CYP3A5*3), present in all 
ethnic groups, in variable frequencies (Figure 10). As a result, individuals homozygous 
for the CYP3A5*3 allele appear to be defective in CYP3A5, as this SNP generates a 
cryptic splice site resulting in the incorporation of the intronic sequence in the mature 
mRNA. This ultimately leads to the production of a truncated protein due to a premature 
termination of translation (Kuehl et al., 2001). The activity of CYP3A5 may be 
important for the metabolism of specific drugs. This was shown for the case of the 
immunosuppressive drug tacrolimus where the plasma concentration and dose 
requirement was clearly demonstrated to be correlated to the presence of the CYP3A5*3 
allele (Hesselink et al., 2003; Thervet et al., 2003). 
  40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – The CYP3A5 gene is constituted by 13 exons (Gellner et al., 2001) that give origin to a protein with 57.1 kDa. CYP3A5 variation is mainly 
due to a SNP present in the intron 3 (6986 A>G) (http://www.cypalleles.ki.se/).  
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The Phase II of metabolism 
Phase II reactions are also called conjugation reactions, whereby the drug 
molecule or its metabolite(s) is coupled with an endogenous hydrophilic substrate. 
These include glutathione, glucuronic acid, sulphate, acetate, bile acid, or an amino 
acid. Major enzymes in Phase II are the UDP glucuronosyltransferase (UGT), 
sulfotransferases (SULT), arylamine N-acetyltransferases (NAT), glutathione S-
transferases (GST), thiopurine S-methyltransferases (TPMT) or the catecholamine-O-
methyltransferases (COMT). In this thesis we focused on the analysis of polymorphisms 
in N-acetyltransferase 2 (NAT2) and Glutathione S-transferase M1 and T1 (GSTM1 and 
GSTT1) genes. 
 
N-Acetyltransferase 2 (NAT2) 
 N-acetylation is the major route of biotransformation for xenobiotics containing 
an aromatic amine (R-NH2) or a hydrazine group (R-NH-NH2). This reaction is 
performed by two cytosolic enzymes, NAT1 and NAT2. The corresponding genes were 
mapped to chromosome 8p21.3-23.1 and each of the two respective genes has a single, 
intronless protein-coding exon with an ORF of 870 bp (Figure 11) (Grant et al., 1989). 
The N-acetyltransferase 2 enzyme encoded by the NAT2 gene plays a primary 
role in the activation and/or inactivation of a diverse number of aromatic amines (e.g., 
procainamide) and hydrazine drugs (e.g., isoniazid) used in therapeutics. NAT2 is 
expressed predominantly in the human liver, being found also in the intestine, placenta, 
bladder or prostate (Boukouvala and Fakis, 2005). The slow NAT2 acetylator, 
characterized by a decreased enzyme activity, is expected to be at higher risk for drug 
side effects (isoniazid and sulfasalazine, Hiratsuka et al., 2002 and Tanaka et al., 2002, 
  42
respectively), while therapeutic failure may be expected in rapid acetylators after 
standard doses (Sabbagh and Darlu, 2006).  
 
The NAT2 allelic variation has been extensively studied, due to its long known 
impact on the acetylator phenotype (Weber, 1987). The “wild-type” NAT2*4 and 35 
NAT2 allelic variants have been identified in human populations, as the result of the 
different combinations of the known SNPs (http://www.louisville.edu/medschool/ 
pharmacology/NAT.htm) (Figure 11).  
Of the alleles described, NAT2*4 is responsible for the fast acetylator phenotype, 
together with NAT2*12A, *12B, *12C and *13 alleles, since these contain 
polymorphisms which are either silent or lead to conservative amino acid changes 
(Cascorbi et al., 1996; Hein et al., 1994; Lin et al., 1993). The remaining NAT2 alleles 
have been demonstrated to code for enzymes with reduced activity and/or stability and, 
therefore, conferring slow acetylator phenotypes (Ferguson et al., 1994; Hein et al., 
1995; Leff et al., 1999). The mutation 191 G>A, previously reported as “African-
specific”, defines the NAT2*14 alleles and is known to have a drastic effect on NAT2 
enzymatic activity, being associated with the slow acetylator phenotype (Fretland et al., 
2001). 
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Figure 11 - The NAT2 gene codes for a 290 amino acids protein (33.5 kDa). The 
conjugation of the 17 nucleotide changes represented in the figure gives origin to 
different allelic variants that are compiled in http://www.louisville.edu/medschool/ 
pharmacology/NAT.htm. The structure of the catalytic N-terminal domain of NAT2 
was determined by homology models with the crystallographic structure of Salmonella 
typhimurium NAT (Rodrigues-Lima and Dupret, 2002). 
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Glutathione S-transferases – GSTM1 and GSTT1 
The Glutathione S-transferase (GST) superfamily of enzymes comprises a range 
of cytosolic, mitochondrial, and microsomal proteins which are capable of multiple 
reactions with a multitude of substrates, both endogenous and exogenous. The GST 
enzymes facilitate the detoxification of various carcinogens, therapeutic drugs, 
environmental toxins and products of oxidative stress (Hayes et al., 2005). These 
enzymes have been described to be involved in the detoxification of anticancer agents 
(e.g. adriamycin, cis-platin or busulfan), environmental chemicals and metabolites (e.g. 
DDT, inorganic arsenic or methyl parathion) and epoxides (e.g. the antibiotic 
fosfomycin, aflatoxin B1, polycyclic aromatic hydrocarbons (PAHs) or styrene) (Hayes 
et al., 2005).  
Different physiological roles have been reported for GSTs besides the 
involvement in the degradation of products resultant from oxidative stress. GSTs are 
also involved in the degradation of aromatic amino acids, synthesis of steroid hormones, 
biosynthesis of important metabolites of arachidonic acid and in the modulation of 
signalling pathways (for a review see Hayes et al., 2005). 
Soluble GSTs are biologically active as like dimeric proteins and at least seven 
distinct classes of soluble GST highly expressed in the mammalian liver have been 
identified: alpha (A), mu (M), pi (P), sigma (S), theta (T), kappa (K), and zeta (Z) 
(Hayes et al., 2005). Although the classes share some overlapping properties, each GST 
isoform possesses unique substrate specificities. These allow the GSTs to provide a 
broad spectrum defence against the potentially damaging effects of a range of 
xenobiotics and endogenously produced toxic compounds.  
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The genes encoding the mu class of enzymes are organized in a gene cluster on 
chromosome 1p13.3 (5' - GSTM4 - GSTM2 - GSTM1 - GSTM5 - 3'). GSTM1 is one of 
the genes in this cluster. It is organized in eight exons, coding for a protein with 217 
aminoacids (Figure 12). GSTM1 is expressed is the liver and also in the kidney (Rowe 
et al., 1997), lung, colon or leukocytes (Anttila et al., 1993; Szarka et al., 1995; Wang 
et al., 2000).  
 
 
 
 
 
 
 
 
 
 
                                                                                                                           
              
 
 
 
Figure 12 – The GSTM1 gene is constituted by eight exons where few variations were 
described (data from Tetlow et al., 2004 and http://pgeni.unc.edu/ ). GSTM1 3D 
structure was obtained from PDB and is presented as homodimer (PDB access number 
1XW6). 
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The theta class includes two members, GSTT1 and GSTT2, and the genes are 
localized in chromosome 22. The GSTT1 gene is located approximately 50kb upstream 
from the GSTT2 gene. Both GSTT1 and GSTT2 were described to be expressed in liver, 
erythrocytes, lung, kidney, brain, skeletal muscles, heart, small intestine, and spleen 
(Juronen et al., 1996). The GSTT1 is composed by five exons and an ORF coding for a 
protein with 239 amino acids (Figure 13).  
 
 
 
 
 
 
 
 
                              
                                                                                        
 
 
 
 
 
Figure 13 – The GSTT1 gene was mapped in chromosome 22 and different variations 
were reported (data from http://pgeni.unc.edu/). The 3D structure of GSTT1 protein was 
obtained from PDB and is presented as homodimer (PDB access number 2C3N). 
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Human cytosolic GSTs display polymorphisms likely to contribute to 
interindividual differences in responses to xenobiotics. The main polymorphism in two 
important isoforms, GSTT1 and GSTM1, is the total deletion of the gene, resulting in 
the complete lack of enzyme activity. Studies in this area addressed the question of 
whether individuals lacking GSTM1 and/or GSTT1 showed a higher incidence of 
common neoplasias, due to decreased protection against xenobiotic carcinogens (Parl, 
2005). Since glutathione-conjugation represents a detoxification pathway, the total 
absence of GSTM1/GSTT1 activity, due to homozygous gene deletion (genotype 
GSTM1*0/*0 and/or GSTT1*0/*0) may be linked to increased drug toxicity or cancer 
susceptibility (Parl, 2005). 
 
Gluthatione S-Transferases and the Oxidative stress in Malaria  
The level of oxidative stress is critical for survival, depending on the balance 
between the production and clearance of reactive oxygen species (ROS). These species 
are generated not only after pathological stress conditions but as the result of normal 
metabolism (aerobic respiration leads to the production of the superoxide anion, 
hydrogen peroxide and the hydroxyl radical). The mammalian cells have developed 
different systems (non-enzymatic and enzymatic) in order to control the levels of ROS. 
These species are scavenged by antioxidants, such as reduced glutathione (GSH), 
ascorbate (vitamin C), and carotenoids and by the catalytic activities of superoxide 
dismutase (SOD) and catalase (CAT) and glutathione peroxidase (GPX). In addition to 
these antioxidants systems we find the GST enzymes. GSTs play an important role in 
the conjugation of GSH to the products of endogenous lipid peroxidation and in the 
inactivation of organic hydroperoxides via selenium-dependent glutathione peroxidase 
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activity (Sharma et al., 2004). These actions protect the cell from the deleterious effects 
of oxidative stress.  
Oxidative stress plays an important role in malaria pathology. When infected by 
P. falciparum the host erythrocyte suffers oxidative aggressions by the parasite 
metabolism and by its own immune system (see section The Human Host – Genetic 
Resistance). The host immune defence system uses the phagocytosis and the production 
of nitric oxide and oxygen radicals to fight the infection, contributing this defence to the 
pathology of the disease (Becker et al., 2004). The oxidative aggressions that come 
from the parasite are the result of the haemoglobin degradation. The antioxidant system 
of the parasite is very efficient and is based in an enzymatic antioxidant defence system 
that includes glutathione- and thioredoxin-dependent proteins. This system is not 
completely efficient and the toxic compounds generated in haemoglobin degradation 
can cause redox damage to the host proteins and membranes, leading to the lysis of the 
erythrocytes or making the RBCs more susceptible to phagocytosis (Becker et al., 
2004). Antimalarials like chloroquine or amodiaquine seem to be associated with an 
increase in the levels of ROS.  
In malaria infection increased levels of ROS were described, as well as a 
decrease in the antioxidants, such as catalase, glutathione peroxidase, glutathione, 
ascorbate or albumin (Pabón et al., 2003; Das and Nanda, 1999). The oxidative stress 
inside the erythrocyte is determinant to the progression of the disease since it is 
involved in the clearance of the parasites (Clark and Hunt, 1983; Greve et al., 1999).  
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Drug Transporters - Multidrug Resistance 1 gene (MDR1, ABCB1) 
The xenobiotic-related transporters (XRTs) consist of uptake and efflux 
transporters, depending of the intracellular or extracellular transport directions. An 
example of uptake carrier systems is the organic anion transporters (OATP, SLC21A).  
Most drug efflux transporters belong to the ATP-binding cassette (ABC) 
superfamily of membrane proteins, which may influence the intracellular concentration 
of numerous compounds. Efflux drug transporters act as barriers, preventing exogenous 
compounds from being absorbed, but when expressed in the hepatocytes or in the 
kidney, they can contribute to excretion (Szakács et al., 2006). In H. sapiens the ABC 
superfamily comprises approximately fifty members, classified in seven subfamilies 
(ABCA to ABCG), a proportion of them being located in the plasma membrane and 
able to extrude a variety of structurally diverse drugs and metabolites (Human ABC 
Proteins Database - http://nutrigene.4t.com/humanabc.htm). Export of these compounds 
occurs in an active, ATP-dependent manner, and can take place against considerable 
concentration gradients. The first member of this superfamily, P-glycoprotein (P-gp), 
was discovered in 1976 and is still the most intensively studied (Juliano and Ling, 1976; 
Couture et al., 2006).  
P-gp protein is coded by the multidrug resistance gene (MDR1, ABCB1), and 
displays a wide substrate specificity including molecules of significant difference in 
structural and chemical characteristics (e.g. anticancer agents, cardiac drugs, HIV 
protease inhibitors, immunosuppressants, antibiotics, steroids or calcium channel 
blockers) (for a list of substrates see Fromm, 2002). P-gp is assumed to represent a 
protective mechanism against potentially toxic xenobiotics, a function that is reflected 
in its most extreme form in the pivotal role of this transporter in anti-cancer drug 
resistance. Its typical normal physiological expression in the apical membrane of 
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normal tissues such as intestine, kidney, liver, and the blood-brain barrier reinforces its 
significant excretory and xenobiotic barrier role (Thiebaut et al., 1987; Cordon-Cardo et 
al., 1990). By contributing for the disposition of a large range of drugs, drug-drug 
interactions are expected to occur when its activity is altered by one drug resulting in a 
change of the clearance of other substrates. 
P-gp was documented to be involved in the disposition of several antimalarials. 
The antimalarials chloroquine, quinine and mefloquine were reported to be weak P-gp 
substrates in vitro (Pereira et al., 1995; Pham et al., 2000; Riffkin et al., 1996; Crowe et 
al., 2006). Recently Hayeshi and collaborators analysed a large number of compounds, 
including quinine, amodiaquine (and DEAQ) and chloroquine and demonstrate in vitro 
that they are P-gp inhibitors but only quinine is a substrate (Hayeshi et al., 2006). 
Another study, this time performed in healthy White travellers, showed that MDR1 
polymorphisms were associated with neuropsychiatric adverse effects of mefloquine, 
particularly in female travellers (Aarnoudse et al., 2006). 
The MDR1 gene is located in the long arm of chromosome 7 (7p21.1) and 
consists in 29 exons (Bodor et al., 2005) that give origin to a protein with 1280 amino 
acids. The protein is phosphorylated and glycosylated and is composed by two 
homologous halves, each one containing six transmembrane segments and an 
intracellular ATP-binding site (Figure 14-A).  
Genetic variants can alter P-gp expression and function. To date more than 40 
SNPs have been found in MDR1 gene distributed by the ORF, promoter and intron 
regions (Kroetz et al., 2003). Among the different SNPs (Figure 14) presently known in 
the MDR1 gene, the -129 T>C, 3435 C>T and 2677 G>T/A polymorphisms have been 
particularly studied and associated to altered P-gp expression and function (Hoffmeyer 
et al., 2000; Kim et al., 2001; Tanabe et al., 2001).  
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Figure 14 – The MDR1 gene with 29 exons extends for over more than 200 Kb. The coding region nonsynonymous SNPs are represented in the figure 
and also the SNP in the promoter -129 T>C and the SNP 3435 C>T in exon 28 (Kroetz et al., 2003; Sakaeda, 2005). A) Schematic drawing of human P-
glycoprotein transporter (Kim et al., 2001). B) Space-filling model of human P-gp protein in the nucleotide bound form (from Sarkadi et al., 2006). 
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The -129 T>C alteration, located in the promoter region, has been associated 
with significantly lower levels of P-gp in placentas of individuals carrying the T/C 
genotype when compared with the T/T genotype (Tanabe et al., 2001). 
Regarding the 3435 C>T, the TT homozygotes were described to have a lower 
level of intestinal P-gp resulting frequently (but not always) in an increase of the probe 
drug digoxin plasma levels, as compared to the CC genotype group (Hoffmeyer et al., 
2000; Kim et al., 2001; Morita et al., 2003; Owen et al., 2005; Sakaeda et al., 2001). 
But, considering that 3435 C>T is a silent mutation, research focused on the reasons 
that could explain these differences. The first hypothesis to solve this question had 
pointed to the existence of a linkage between this SNP and others functional alterations. 
The 2677 G>T/A SNP was described to be in linkage disequilibrium with 3435 C>T 
and proposed to be the main responsible for the phenotype associations with the later 
polymorphism (Kim et al., 2001). However, the linkage is normally not observed in 
100% of the cases. Another hypothesis appeared in 2005 when a quantitative analysis of 
allelic 3435 C>T P-gp expression in liver samples and cell lines revealed that livers 
harbouring TT express significantly less mRNA than the ones containing 3435CC and 
that the SNP was associated with a decrease in the mRNA stability (Wang et al., 2005). 
A recent study performed by Kimchi-Sarfaty and collaborators at the National Institute 
of Health, Bethesda, may have found the main answer since they have shown that the 
3435 C>T silent mutation alters the coded protein substrate specificity (Kimchi-Sarfaty 
et al., 2007). It was suggested that this happens because of the presence of a less 
commom codon (considering the typical H. sapiens codon usage – 
http://www.kazusa.or.jp/codon/) that affects the timing of co-translational folding and 
further insertion of P-gp into the membrane (Kimchi-Sarfaty et al., 2007). The 
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additional time spend in this process can alter the structure of substrate and inhibitor 
sites (Kimchi-Sarfaty et al., 2007). 
 
Pregnane X receptor (PXR, NR1I2) 
Nuclear receptors (NRs) such as the pregnane X receptor (PXR, NR1I2) and the 
constitutive androstane receptor (CAR, NR1I3) play an important role in protecting the 
body against toxic xenobiotics. NRs are a large class of ligand activated transcription 
factors that function to regulate a wide array of cellular processes (Alarid, 2006). 
PXR is a xenobiotic-induced nuclear receptor identified as a transcriptional 
regulator controlling the expression of numerous proteins which are collectively 
involved in the metabolism and excretion of lipophilic substances from the body. 
Among them are phase I enzymes such as CYP1A1, 1A2, 2A6, 2B6, 2C8, 3A4 and 
3A5, phase II enzymes like GSTs, UGTs and SULTs, and membrane transporters such 
as P-gp and MRP2 (Maglich et al., 2002; Tirona and Kim, 2005).  
This nuclear receptor was identified independently in 1998 by three different 
groups as a protein involved in the induction of the cytochromes P450, in particularly 
CYP3As, and was named PAR, SXR and PXR, depending of the publication (Bertilsson 
et al., 1998; Blumberg et al., 1998; Kliewer et al., 1998). In 2001 the human PXR gene 
with 38 Kb was located at the chromosome 3q13-q21 (Zhang et al., 2001). It comprises 
9 exons and the translation start site is located in exon 2 encoding a protein with 434 
amino acids. The analysis of human PXR has shown a multiplicity of transcripts and 10 
protein isoforms have been documented (Figure 15) (Lamba et al., 2004; Kurose et al., 
2005; Fukuen et al., 2002a). Studies that show the tissue distribution of the variants or 
their importance in the induction of the target genes are still lacking.  
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The structure of the PXR protein is similar to other nuclear receptors with a 
highly conserved DNA binding domain (DBD) linked via a flexible hinge region to the 
ligand-binding domain (LBD) (Carnahan and Redinbo, 2005). Contrary to other nuclear 
receptors, PXR is very promiscuous capable of biding a variety of structurally diverse 
ligands. It has a ligand-binding pocket unusually large (> 1100 Å3) and flexible, 
spherical in shape and extremely hydrophobic (twenty of the twenty eight residues in 
the ligand-biding pocket are hydrophobic) (Watkins et al., 2001; Orans et al., 2005; for 
a review in structure and function of PXR see Carnahan and Redinbo, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 – Schematic representation of the hPXR alternative mRNAs (adapted from 
Fukuen et al., 2002a). The exons are numbered and boxed and shaded in dark are the 
insertions. For complete skipping the exon number is missing.  The termination codons 
of open reading frame are depicted as asterisks.  
 
 
                 
1 2 3 4 6 5 7 8 9 
2 3 4 6 5 7 8 9 
1 2 3 4 6 7 8 9 
1 2 3 4 6 7 8 9 
1 2 3 4 6 7 8 9 
1 6 5 7 8 9 
1 2 3 4 6 7 8 9 
1 2 3 4 7 8 9 
1 3 4 6 7 8 9 
1 4 6 7 8 9 
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In 2001 Zhang and collaborators, as well as Hustert and collaborators, 
simultaneously described several SNPs both in the coding and non-coding regions of 
the PXR gene (Figure 16), associated with individual phenotype variations in basal and 
rifampin inducible expression of CYP3A and P-gp (Zhang et al., 2001; Hustert et al., 
2001a). In addition to this original description of SNPs in PXR, additional 
polymorphisms have been described since then (Koyano et al., 2002; Koyano et al., 
2004; Lim et al., 2005; for a review in the genetic variation of PXR see Lamba et al., 
2005; http://www.hapmap.org).   
From the different variants described in 2001, the 7635 A>G and 8055 C>T 
SNPs localized in intron 5 and 6, respectively were associated with a higher induction 
activity of PXR, with the consequent increase in erythromycin metabolism after 
rifampicin treatment. Two SNPs localized in the 3’ untranslated region, the 11156 A>C 
and 11193 T>C SNPs were correlated with decreased P-gp levels in the gut (Zhang et 
al., 2001). The different variants identified in PXR gene can lead to altered induction 
transcription rates of target genes. These may affect the disposition of many currently 
administrated drugs, metabolised and transported by PXR induced proteins. Ultimately, 
polymorphisms in PXR leading to functional changes in this receptor may play a key 
role in the regulation of drug response. 
 The antimalarial chemotherapy includes many drugs that are substrates of XMEs 
and/or XRTs regulated by PXR. A new connection to this receptor was established with 
the discovery that artemisinin and the derivatives artemether and artesunate activate and 
act as ligands of human PXR (and also CAR). This leads to the induction of the 
expression of different CYPs and the transporter P-gp (Burk et al., 2005). By in vitro 
methods the authors showed that artemisinin drugs induce the expression of CYP2B6, 
CYP3A4 and MDR1. 
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Figure 16 – The genomic structure of PXR gene was characterized in 2001 (Zhang et al., 2001) and different nucleotide variants were identified since 
then. The coding SNPs are represented (data from Lamba et al., 2005). The structure of PXR LBD was determined in 2001 (Watkins et al., 2001) and 
the 3D from PDB is shown (PDB access number 1ILG). 
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AIMS OF THE STUDY 
 
The overall aim of this thesis was: 
A. The study of the genetic variability in enzymes involved in drug metabolism, 
especially in populations from regions where malaria represents a major public 
health issue. A particular emphasys was given to the antimalarial drug amodiaquine. 
B. The possible contribution of XMEs associated to the management of REDOX stress 
in the susceptibility to the disease. 
   
Specific aims of the study were: 
• To develop new genotyping methods to study the variation in genes that code for 
enzymes involved in drug metabolism, membrane transporters and transcription 
factors. Development and optimisation of methodology was performed in the 
Portuguese population. This population was also the comparator Caucasian 
population. 
• To study the variability of CYP2C8 in the Zanzibar islands and its possible influence 
in the efficacy of amodiaquine. This was followed by the characterization of 
CYP2C8 in different countries from Africa, Southeast Asia and South America, 
namely Sao Tome and Principe, Guinea-Bissau, Thailand and Colombia. 
• To characterize the variability of CYP3A5 and PXR in Sao Tome and Principe, 
Guinea-Bissau and Thailand. 
• To investigate the enzymes responsible for the metabolism of desethylamodiaquine 
and posterior study of the variability of the enzymes involved. 
• To analyse the influence of the deletion of GSTM1 and GSTT1 genes in the 
pathology of uncomplicated malaria. 
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METHODS 
 
 
Genotyping Studies 
Studied populations 
In Studies I, IV and VII, healthy Caucasian Portuguese subjects from local 
medical check-ups were included in genotyping studies. Blood samples obtained from 
individuals of the Balanta ethnic group from Guinea-Bissau (Nhacra sector, a rural area 
between the rivers Mansoa and Geba, 26 to 51 Km from the capital) were included in 
Study II. Concerning Study III and the Study of CYP1A1 and CYP1B1 
polymorphisms, the studied population comprised unrelated Zanzibari children with 
uncomplicated malaria from Unguja (Uzini Health Care Unit) and Pemba (Konde 
Health Care Unit). In Study V and Study VII unrelated subjects from Sao Tome and 
Principe, Guinea-Bissau and Thailand were analysed. A randomely selected population 
from Colombia was also genotyped in Study V.  
 
Genotyping Methods 
 
 Genotyping is a procedure that allows the determination of frequencies of allelic 
variants in a certain gene. This is accomplished by the analysis of DNA extracted from 
different origins (e.g. a blood sample or a buccal swab). Different methods are available 
for genotyping - polymerase chain reaction (PCR), restriction fragment length 
polymorphism (RFLP), single stranded conformation polymorphism (SSCP), 
sequencing, real-time PCR using TaqMan probes and microarrays, to mention the most 
common.  
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The genotyping methods used in Study I to V, VII and in the Study of CYP1A1 
and CYP1B1 polymorphisms were based on PCR-RFLP analysis and analysed SNPs in 
the following genes: CYP1A1 (2455 A>G), CYP1B1 (4326 C>G; 4360 C>G; 4390 
A>G), CYP2C8 (416 G>A; 1196 A>G; 792 C>G; 805 A>T), CYP3A4 (-392 A>G; 673 
T>C), CYP3A5 (6986 A>G), NAT2 (191 A>G), MDR1 (-129 T>C; 3435 C>T; 2677 
G>T) and PXR (7635 A>G; 8055 C>T; 11156 A>C; 11193 T>C).  
In the analysis of CYP1B1 polymorphisms, sequencing was used for the study of 
CYP1B1 SNPs 142 C>G and 355 G>T. The sequencing was performed in Macrogen 
(www.macrogen.com, Seoul National University, Seoul, Korea) and the analysis of the 
results was made using the Chromas© software (McCarthy, Queensland, Australia) 
 
The primers and enzymes used in the different studies are presented in Table 2. 
Specific assays were designed or were adopted from previous reports. 
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Influence of CYP2C8 polymorphism in AQ therapy  
Experimental design 
In Study VI the studied population comprised a control group of 110 children 
(patients with a positive outcome) and a case group of 63 children with recurrent 
infection, both groups with uncomplicated malaria. The population analyzed is from the 
two Zanzibar islands, Pemba (controls n = 44; cases n = 53) and Unguja (controls n = 
66; cases n = 10). These children were treated with the first line treatment based on 
three daily doses of amodiaquine-artesunate (4 mg/Kg artesunate + 10 mg/Kg 
amodiaquine). As a comparator, another group of 96 controls (Pemba n = 34; Unguja n 
= 62) and 56 cases (Pemba n = 49; Unguja n = 7) were also included in the study 
corresponding to treatments with the second line treatment of six doses of a 
lumefantrine-artemether fixed combination (Coartem®, Novartis AG, Basel, 
Switzerland) (1 to 4 tablet twice daily, 20 mg of artemether and 120 mg of lumefantrine 
per tablet). 
CYP2C8 SNPs 416 G>A, 792 C>G and 805 A>T were analysed using the same 
PCR-RFLP methods applied in the Study III (Table 2). To confirm the presence of 
heterozygous patterns in the case of 416 G>A (R139K) the samples were genotyped 
using Real Time PCR 5’-exonuclease based Taqman® assays (Applied Biosystems, 
Fresno, CA, USA) with the recommended protocol, in an ABI PRISM 7000 Sequence 
Detection System (Applied Biosystems, Fresno, CA, USA). 
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Table 2 – PCR oligonucleotide primers used for RFLP analysis and sequencing of the different genes (lower case denotes the introduction of nucleotide 
mismatches for the generation of restriction enzyme cleaving sequences). 
Detected Polymorphism PCR-RFLP Conditions Reference 
 Primers 5’ – 3’ Analysis of the SNP  
 
NAT2 
  
  
191 G>A Fw1 - GAT CAC ATT GTA AGA AGA AAC CG 
Rv1 - GGA TGA AAG TAT TTG ATG TTT AGG 
Fw2 - GAT CAC ATT GTA AGA AGA AAC CG 
Rv2 - TTG GGT GAT ACA TAC ACA AGG G 
Msp I Study II 
 
CYP3A4 
 
   
-392 A>G Fw - AAT GAG GAC AGC CAT AGA GAC AAG GcC 
Rv - CAA TCA ATG TTA CTG GGG AGT CCA AGG G 
Bst NI Study I and II 
673 T>C Fw - AGA TTT GAT TTT TTG GAT CCA TTC TTT gTC 
Rv - CAA ATC ACT GAA CTG TAT ATT TTA AGT GG 
Alw26 I Study I 
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MDR1 
 
   
-129 T>C Fw - TCT CGA GGA ATC AGC ATT CAG TCA ATC C 
Rv - CTA AAG GAA ACG AAG AGC GGC CTC TG 
MspA1 I Study I 
3435 C>T Fw - ATG GGC TCC GAG CAC ACC TG 
Rv - AGG CAG TGA CTC GAT GAA GGC 
Sau3A I Study I 
2677 G>T Fw - GTA CCC ATC ATT GCA ATA GCA 
Rv - TTT AGT TTG ACT CAC CTT CCg AG 
Alw21 I Study I 
 
CYP2C8 
 
   
416 G>A Fw - AGG CAA TTC CCC AAT ATC TC 
Rv - ACT CCT CCA CAA GGC AGT GA 
BseR I Dai et al., 2001 
1196 A>G Fw - CTT CCG TGC TAC ATG ATG ACG 
Rv - CTG CTG AGA AAG GCA TGA AG 
Bcl I Study III - V 
792 C>G, 805 A>T Fw - ATG TTG CTC TTA CAC GAA GTT ACA 
Rv - ATC TTA CCT GCT CCA TTT TGA 
Taq I / Bcl I Bahadur et al., 2002 
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CYP3A5 
 
   
6986 A>G Fw - TGA GCA CTT GAT GAT TTA CC 
RV - GGT CCA AAC AGG GAA GAG gT  
Rsa I Study VII 
 
PXR 
 
   
7635 A>G Fw - GCACTAGCTGTAGGTCAGGA 
Rv - CAGCAGCCATCCCATCATCAA 
Hph I Study VII 
8055 C>T Fw - TTGCTGAGAAGCTGCCCCTCgAT 
Rv -  AGGAGCAAGGCCATAGACTGG 
Hinf I Study VII 
11156 A>C 
11193 T>C 
Fw - CACACCGGAGAAGAACCATT 
Rv – TCTTACGCCGGAGTCTTCA 
Dde I / Bsi YI Study VII 
 
CYP1A1    
2455 A>G Fw - CGG TTT CTC ACC CCT GAT GGT GCT A  
Rv – CTC AAG CAC CTA AGA GCG CA 
Bse MI - 
  64 
 
CYP1B1    
4326 C>G Fw  – GTC AAC CAG TGG TCT GTG AAT CAT GA 
Rv  – CTG CAT CTT AGA AAG TTC TTC GCC A 
Bse NI - 
4360 C>G 
4390 A>G 
Fw  – ACC TGC CCT ATG TCC TGG CCT TCC T 
Rv  – CTG CAT CTT AGA AAG TTC TTC GCC A 
Alu I 
Mwo I 
- 
142 C>G 
355 G>T 
Fw- CACGCTCCTGCTACTCCTGTCG 
Rev- AGAAGTTGCGCATCATGCTG 
SEQ- AGTAGTGGCCGAAAGC 
Amplification 
 
Sequencing primer 
- 
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Metabolic pathways of DEAQ – The role of CYP1A1 
 
Microsomal incubations 
Human liver microsomes (HLM) are fractionated from other subcellular 
organelles by differential ultracentrifugation. In vivo clearances of several substrates can 
be accurately predicted using the substrate loss method with incubations using human 
liver microsomes (Mohutsky et al., 2006).  
Microsomes from human livers previously prepared and characterized (Westlind 
et al., 1999) were used in this study. The first experiment was performed using 100 µM 
of DEAQ. In the other incubation a linear range regarding the concentration of drug (0 
mM to 2 mM) was used. NADPH was used as co-enzyme in a final concentration of 1 
mM. The reactions were allowed to proceed at +37ºC in a water bath for 20 minutes and 
were ended with the addition of ice-cold acetonitrile in a proportion of 50:50. Samples 
were immediately put on ice and stored at -80ºC until further analysis. 
In all incubations duplicate samples were run, in parallel with controls without 
the presence of NADPH. 
 
InVitroSomes™ 
 Incubations using the InVitroSomes™ sample kit (InVitro Technologies, Inc., 
Baltimore, Maryland, USA) were performed following the instructions of the 
manufacturer. The kit consists in human cytochrome P450 enzymes and CYP-reductase 
co-expressed in Saccharomyces cerevisiae. The kit includes ten human recombinant 
CYPs: CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2D6, 
CYP2E1, CYP3A4 and CYP3A5.  
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In the experiment a concentration of 100 µM of DEAQ was tested. After an 
incubation of 30 minutes or 1 hour at +37ºC, reactions were terminated with the 
addition of ice-cold acetonitrile in a proportion of 50:50. Samples were immediately put 
on ice and stored at -80ºC until further analysis. In the case of the 30 minutes 
incubation, duplicate samples were run. NADPH was used as co-enzyme and in both 
runs a control sample was included. 
   
Chemical assay 
Drug concentration determinations were conducted at Gothenburg University, 
Gothenburg, Sweden. Samples were thawed at room temperature. Following vortex 
mixing and a brief centrifugation at 3400 rpm for 5 minutes, 50µL was transferred to a 
new tube and 180 mL of phosphate buffer pH 2.0 was added. The concentration of 
DEAQ was determined using a previously described HPLC method with a Zorbax SB-
CN column (Chromtech AB, Hägersten, Sweden) and UV detection at 242 nm 
(Lindegardh et al., 2002). Linear calibration curves were generated by log-
transformation of both axes. The coefficient of variation (CV) in quality control samples 
for DEAQ was 15 %, 4 %, and 4 % at 10, 75 and 1000 µM respectively. The lower limit 
of quantification (LLOQ) was set at 3 nM (CV was 13 %).  
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CYP1A1 sequencing  
 The microsomal incubations indicated that CYP1A1 was the enzyme involved in 
the metabolism of DEAQ. To evaluate the role of CYP1A1 gene variability in the 
treatment outcome a search for new mutations in the gene was performed. DNA from 
malaria patients from Papua New Guinea (n= 19) and Zanzibar (n= 12) was used to 
sequence CYP1A1 exons and part of the introns and promoter region.  These patients 
were characterized in terms of AQ and DEAQ pharmacokinetics and were genotyped 
for the main CYP2C8 SNPs (Hombhanje et al., 2005; Friberg Hietala et al., 2007). 
Specific primers were designed for the amplification and sequencing of 
CYP1A1 using the sequence NC_000015 (Table 3). A long PCR was performed to 
amplify a fragment encompassing all the exons and introns after the initiation codon. 
This fragment of 3023 bp was used to amplify four smaller sequences analysed by 
sequencing in Macrogen (www.macrogen.com, Seoul National University, Seoul, 
Korea). Sequencing analysis was performed using the Chromas© (McCarthy, 
Queensland, Australia) and the SequencherTM software (Gene Codes Corporation, Ann 
Arbor Michigan, USA). 
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Table 3 – Sequence of the primers used for CYP1A1 amplification and sequencing. 
 Primers 5’ – 3’ Fragment length (bp) 
1st Amplification 
(Long PCR) 
GTC TGC ATC CAA CAC TTT CTG 
CAG GCT GAA CCT TAG ACC ACA 
3023 
Fragment 1 AGT AAG CAG TTC TGG TGG AAA G 
CAG TTC CTC TTA CCT TTG ACC T 
1045 
Fragment 2 TCA TCC CTA TTC TTC GCT ACC 
CTT AGG TAG GGA AAG TCC ACA 
674 
Fragment 3 TGT GCT AGG AAT AGT GAA GGA C 
CTT TCC TCT GCA TCT CTG AAC 
865 
Fragment 4 CCA CTG CTG TCT GTT ACT GAT C 
CAG GCT GAA CCT TAG ACC ACA 
788 
 
Pyrosequencing analysis of CYP1A1 
New sequence variation in CYP1A1 promoter was observed by the analysis of 
the sequencing results. To confirm three of these variations a pyrosequencing assay was 
developed, since their proximity in the gene did not allow the use of other methods. The 
protocol for analysis was designed with the aid of the PyrosequencingTM Assay Design 
Software, version 1.0 (Biotage AB, Uppsala, Sweden). The primers used for the 
amplification of the fragment were FW 5’- GTT TCC CCT TTC CCT GAC A – 3’ and 
RV 5’ – GAG AGA AGG TGC AGG AAG AAA AAA – 3’ and the primer for the 
sequencing reaction was 5’ – CCT TTC CCT GAC ACT CTA – 3’. Samples were 
analyzed on a PSQTM 96MA instrument using pyrosequencing software PSQTM96MA 
(Biotage, Uppsala, Sweden). 
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The role of GSTM1 and T1 in uncomplicated malaria  
 
In Study VIII a group of 1885 patients from Unguja (Uzini Health Care Unit) 
and Pemba (Konde Health Care Unit) were analysed. Among these, 1515 patients 
corresponded to selected children with uncomplicated malaria. A group of 370 patients 
enrolled in this study were verified to be negative for the presence of P. falciparum and 
were used as controls. 
 The analysis of GSTM1 and GSTT1 deletion polymorphism was performed 
adapting a PCR mutiplex method (amplification of GSTM1, GSTT1 and a control gene 
(CYP1A1)) described by Abdel-Rahman and co-workers (Abdel-Rahman et al., 1996).  
 
Statistical analysis 
Allelic frequencies and confidence intervals were assessed using the program 
CIA (Confidence Interval Analysis) (Gardner and Altman, 1989). Chi-square (χ2) 
testing was performed with Microstat® software (Ecosoft Inc, Indianapolis, IN, USA) 
and GraphPad software (www.graphpad.com). For the evaluation of Hardy-Weinberg 
equilibrium on the analyzed SNPs the GenePop software pack was applied 
(http://wbiomed.curtin.edu.au/genepop/). The PXR haplotypes and frequencies were 
obtained by the PHASE Version 2 Software (Stephens et al., 2001; Stephens and 
Donnelly, 2003; http://stephenslab.uchicago.edu/software.html).  
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RESULTS AND DISCUSSION 
Details of the results are found in the papers I-VIII. 
 
Genotyping Studies 
The use of genotyping determination and phenotyping measurements of drugs 
and/or drug metabolites aims to evaluate the clinical significance of the genotype for the 
variability in response and side effects. As such, the connection is made between the 
SNPs in a candidate gene and alterations in pharmacokinetics and/or the clinical 
outcome. 
The common use of phenotyping measurements (e.g. drug pharmacokinetics) in 
a Developing World typical malaria scenario is far way from becoming a reality, due to 
several logistic reasons, further aggravated by the characteristic young age of the 
majority of the malaria patients in those settings. At this stage, pharmacogenetic 
information about the region’s most representative population of malaria patients can be 
relevant. A better knowledge of the genetic variability in populations from these settings 
could be an important background for the future pharmaco-vigilance initiatives. In this 
thesis genotyping studies evaluated the interethnic variability in populations from 
regions where this information is very limited or even absent.  
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Study I - CYP3A4 and MDR1 alleles in a Portuguese population  
 
The pharmacogenetic characteristics of the Portuguese were assumed as a 
Caucasian comparator for further discussion with the several non-European populations 
herein analysed. 
In a sample of one hundred unrelated subjects representative of the Caucasian 
Portuguese population two genes coding for proteins with a major role in drug 
disposition were analysed: CYP3A4 and MDR1. The frequencies of CYP3A4*1B (-392 
A>G) and CYP3A4*2 (673 T>C) were found to be 4.0% and 4.5%, respectively, with 
no homozygous individuals observed for both alleles (Table 4). Concerning the MDR1 
gene, two of the three variant alleles analysed were present in high frequencies, 3435T 
with 64.5% and 2677T with 47.5% (Table 4); in the case of the -129 T>C SNP, the 
presence of the C allele was observed in a frequency of 5.0%. Linkage between the 
3435 C>T/ 2677 G>T SNPs was observed, with an association of 3435 C/C with 2677 
G/G genotypes in a frequency of 25.8%. We did not find any individual carrying the 
3435 C/C associated with 2677 T/T and no significant linkage was observed between 
the -129 T>C SNP and the other MDR1 polymorphic positions here analysed.  
The description of CYP3A4 and MDR1 SNPs frequencies was the first in the 
Portuguese population, except for the case of 3435 C>T in MDR1 previously included 
as one of several populations described by Ameyaw and collaborators (Ameyaw et al., 
2001). The frequency observed in our study for 3435 C>T (64.5%) does not differ 
significantly from the previously reported in that study conducted in the Centre-North 
regions of Portugal (57.0%). 
The existence of linkage disequilibrium between the synonymous 3435 C>T and 
2677 G>T/A (and 1236 C>T) was proposed in 2001 in an attempt to explain the 
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phenotype associated with 3435 C>T (Kim et al., 2001; Tanabe et al., 2001).The 
linkage described in the initial reports was around 94% in Japanese, 62% in Caucasian 
Americans but only 13% in African-Americans, showing a high degree of variability in 
different populations. In our study the degree of linkage was found to be only of 25%, a 
value markedely below the registered before. This variability may indicate that the 
existence of a linkage is not the only explanation for the phenotype observations 
associated with 3435 C>T. Also, the studies where the influence of MDR1 SNPs on the 
disposition of P-gp substrates or treatment outcome was evaluated do not show a 
conclusive influence of 2677 G>T/A and 3435C>T (Drescher et al., 2002; Owen et al., 
2005). 
In the absence of results that could fully explain the effect of 3435 C>T in terms 
of phenotype, the research in the field continued and recently it was shown that 3435 
C>T affects the mRNA stability (Wang et al., 2005) and/or alters the substrate 
specificity through the disturbance of the native folding of the protein (Kimchi-Sarfaty 
et al., 2007). In particular, this last report challenges the current paradigm by showing 
that is possible for a synonymous SNP to markedly influence the functionality of the 
coded protein. The study revealed that the changes observed in vitro in the phenotype 
were not due to the presence of 2677 G>T, that the haplotype 1236C>T – 2677G>T – 
3435C>T was associated with similar mRNA or protein levels and that this haplotype is 
associated with slight alterations in the tertiary structure. More, the authors show that 
the MDR1 haplotype can have an important role in the cases where higher levels of 
mRNA are present, and by consequence more P-gp is being translated. The authors 
hypothesise that with a higher production of P-gp, the role of codon usage may become 
critical when certain tRNA species become depleted. They show the presence of lower 
percentages of codon usage when different MDR1 variants are present. With these 
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results the authors presents the hypothesis that when frequent codons are changed and 
replaced by rare codons it may result in altered function, by alterations in the co-
translational folding (Kimchi-Sarfaty et al., 2007). 
 
Table 4 - CYP3A4 and MDR1 Single Nucleotide Polymorphism frequencies in the 
studied Portuguese population (n= 100). 
 Genotype Frequency (95% CI) Allele Frequency (95% CI) 
CYP3A4     
-392 A>G A/A 0.920 (0.848 – 0.965) A 0.960 (0.923 – 0.983) 
 A/G 0.080 (0.035 – 0.152) G 0.040 (0.017 – 0.077) 
 G/G 0 (0.000 – 0.0362)   
673 T>C T/T 0.910 (0.836 – 0.958) T 0.955 (0.916 – 0.979) 
 T/C 0.090 (0.042 – 0.164) C 0.045 (0.021 – 0.084) 
 C/C 0 (0.000 – 0.0362)   
MDR1     
-129 T>C T/T 0.910 (0.836 – 0.958) T 0.950 (0.910 – 0.976) 
 T/C 0.080 (0.035 – 0.152) C 0.050 (0.024 – 0.900) 
 C/C 0.010 (0.0003 – 0.055)   
3435 C>T C/C 0.120 (0.064 – 0.200) C 0.355 (0.289 – 0.421) 
 C/T 0.470 (0.369 – 0.572) T 0.645 (0.579 – 0.711) 
 T/T 0.410 (0.313 – 0.513)   
2677 G>T* G/G 0.310 (0.221 – 0.410) G 0.525 (0.456 – 0.594) 
 G/T 0.430 (0.331 – 0.533) T 0.475 (0.406 – 0.544) 
 T/T 0.260 (0.177 – 0.357)   
 
*The rare G2677A variant was not analysed in this study. Due to its low frequency 
among Caucasians, we believe that its discrimination would not change significantly the 
results and conclusions of this work.  
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These new data show how a non-synonymous mutation can be important to a 
final phenotype and have to be considered as being the basis for some current diseases, 
as well as for variable drug efficacy. 
 
Study II - Cytochrome P450 3A4 and N-acetyltransferase 2 genetic 
polymorphism in a native African population 
 
In Study II we determined the frequency of CYP3A4*1B in native subjects from 
Guinea-Bissau, using the method previously developed for the analysis of the 
Portuguese population. The same population was also analysed for one of the major 
function-altering SNPs in the NAT2 gene, 191 G>A. This study included patients from 
the Balanta ethnic group, a rural population from Guinea-Bissau, where another study 
had previously shown that there is a high prevalence of TB, in strong association with 
HIV-2 infection (Antunes et al., 2002). Guinea-Bissau is a country with poor health 
infrastructures, while facing the burden of several major infectious diseases, such as TB, 
typhoid fever, bacillary dysentery, the aforementioned HIV/AIDS and malaria. Malaria 
is endemic with stable transmission. Guinea-Bissau has recently officially adopted the 
ACT as first line treatment (AL) in the control of the disease (Figure 5). Full 
implementation of ACT in this country is several years away, with CQ still being the 
main drug present and applied in public health centers throughout the territory, since it 
is very inexpensive and still effective (Kofoed et al., 2007; Ursing et al., 2007a) and 
readily available.  
At the time of the study, the CYP3A4*1B polymorphism was chosen for two 
reasons: it was the polymorphism most extensively documented for its functional effect, 
and it had been described as frequent in African-Americans.  
  75
After our study was performed, new data appeared relating CYP3A4 and the 
metabolism of antimalarial drugs. Adding to the long known role of CYP3A4 in the 
metabolism of quinine, this enzyme has also been recently reported to play a role in the 
metabolism of CQ (Projean et al., 2003) and CYP3A4*1B has been specifically 
associated with a protein that presents a reduced in vivo metabolism for quinine 
(Rodriguez-Antona et al., 2005).  
In the 50 Guinea-Bissau patients analysed we determined a frequency of 72.0% 
for CYP3A4*1B (-392 A>G) allele, which corresponds to the presence of 18 
heterozygotes and 27 homozygotes with the altered sequence. This suggests that a high 
percentage of the population can have in circulation higher doses of CQ compared with 
individuals bearing CYP3A4*1 alleles (if we assume that CQ follows the same pattern 
of quinine, however we have to take in account that the PK characteristics of the drugs 
are very different). These doses are expected to be even higher if we take into account 
that the use of CQ in Guinea-Bissau does not normally follow the WHO 
recommendations of 25 mg/kg (10+10+5, 3 days), being used in higher concentrations, 
up to 75 mg/Kg in a different schedule (Kofoed et al., 2002; Ursing et al., 2007b). The 
existence of acute toxicity with the higher dosage was, however, not reported (Kofoed 
et al., 2002).  
Besides malaria, tuberculosis (TB) is also a public health problem in Guinea-
Bissau, which, as other countries in the world, has implemented the DOTS policy 
(Direct Observed Treatment Strategy, the internationally recommended control strategy 
for TB). In a WHO report from 2007 the coverage of DOTS in Guinea-Bissau was 
reported to be 85% (WHO, 2007). The standard treatment regimen implemented for 
previously untreated patients consists of 2 months of streptomycin, isoniazid, rifampin 
and pyrazinamide, followed by 6 months of isoniazid and ethambutol (the 2SHRZ/6HE 
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regimen). Isoniazid (INH) is an important component of this anti-TB chemotherapy and 
it is extensively metabolised in the liver by the polymorphic NAT2. 
 The 191 G>A SNP in the NAT2 gene, associated with slow acetylation, was 
suggested to be of African origin by Bell and co-workers, in their early descriptions in 
African-Americans (Bell et al., 1993). Although studies of the effect of NAT2 
genotypes on the plasma concentration of INH had been performed in different 
populations, the effect of 191 G>A SNP was not evaluated since this allele was not 
present in the previously studied populations. 
We determined the frequency of this variant in 125 Balanta subjects and found a 
prevalence of 19.2%. As such, an important percentage of the population is expected to 
display a slow acetylator phenotype, which means that they may accumulate higher 
circulating levels of INH. This drug is, long known, to be associated to serious adverse 
effects such as hepatotoxicity, peripheral neuropathy and/or agranulocytosis (Forget and 
Menzies, 2006). A high frequency of slow acetylator individuals (>15%) may also be 
the basis for an increased incidence of INH driven drug-drug interactions, as this drug is 
documented to inhibit several drug metabolizing CYPs (e.g., CYP2A6, CYP2C9, 
CYP2C19 and CYP3A4) (Wen et al., 2002; Nishimura et al., 2004).  When this effect 
of INH in the inhibition of different CYPs was tested, only standard drugs like coumarin 
(CYP2A6), warfarin (CYP2C9), mephenytoin (CYP2C19) or midazolam (CYP3A4) 
were used.  
In a country like Guinea-Bissau where beside the chemotherapy against TB, the 
same individual can be also subjected to antimalarial and/or anti-HIV/AIDS 
chemotherapy, the problem of drug-drug interactions can take important proportions 
that normally are not evaluated. A recent study, however, had analysed the interaction 
between amodiaquine plus artesunate and efavirenz and showed the existence of 
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hepatotoxicity due to a drug interation (German et al., 2007). They show that the 
administration of efavirenz togheter with AS+AQ lead to an increase in AQ exposure 
and decrease in DEAQ exposure, and to increased levels of liver-associated enzymes 
after the administration of both regimens of drugs (alanine aminotransferases and 
aspartate aminotransferase) (German et al., 2007). With this first report showing that 
interations between antimalarial and anti-HIV/AIDS chemotherapy can lead to toxic 
events it is important try to evaluate the real consequences of the co-administration of 
drugs. 
The full sequencing of the NAT2 gene was futher performed in a population of 
Vietnam (side study not formally included in the frame of this thesis – see Other 
publications). The results obtained revealed a high frequency (90.8%) of at least one 
NAT2 fast allele, particularly associated to NAT2*13. While this allele is commonly 
observed at frequencies ≤ 5%, in this study it was detected at a prevalence of 34.3%, 
significantly different (P < 0.0001) from any other population previously analyzed in 
the region, including studies in Thailand (< 5.1%; χ2=64.39) (Kukongviriyapan et al., 
2003) and Cambodia (*13 not detected; χ2 = 31.64) (Bechtel et al., 2001). Different 
SNPs are absent in this population, including the 191 G>A SNP common in the Guinea-
Bissau analysed population. The SNPs of the NAT2*7 allele are among those that were 
not observed in the analysis of this Vietnamese population, which is in a clear contrast 
with the results reported for NAT2*7 in Thailand (20.4%) and Cambodia (6.3%).  
 The differences in the percentage of slow acetylators in the populations might 
lead to differences in the incidence of adverse effects caused by over-exposure to INH 
and also in the incidence of INH driven drug-drug interactions (both higher in 
populations with high frequencies of slow acetylators) (the effect of acetylator status on 
drug response and toxicity is summarized in Butcher et al., 2002). 
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Study III, IV and V – CYP2C8 polymorphism in different populations 
 
As previously mentioned, CYP2C8 is an important enzyme in the metabolism of 
CQ and the main responsible for the metabolism of AQ. PCR-RFLP methods for the 
detection of CYP2C8 major alleles were developed and optimized. The results obtained 
in the Portuguese population (Study IV) show a distribution of 1.2% for CYP2C8*2, 
19.8% for 2C8*3 and 6.4% for 2C8*4 (Table 5). CYP2C8*3 was the more frequent 
allele in line with the other reports in Caucasian populations (e.g. United Kingdom, 
Western Germany or Central Spain) (Bahadur et al., 2002; Weise et al., 2004; Garcia-
Martin et al., 2004). The same trend is not observed in native African populations 
(Table 5), where CYP2C8*2 allele is the more frequent instead of CYP2C8*3.  
CYP2C8 has been described as playing a role in the endogenous metabolism in 
biosynthesis of vasoactive factors (Fleming, 2004). CYP2C8*3 allele has been 
associated to a higher risk of acute myocardial infarction (Yasar et al., 2003). The high 
frequency of this allele among the Portuguese and in other Caucasian populations lead 
to a hypothesis that the CYP2C8*3 may be a possible factor in individual elevated risk 
for the development of cardiovascular diseases. It would be of value to study a possible 
association between specific CYP2C8 alleles and the risk of cardiovascular diseases in 
the Portuguese population.  
 
The characterization of CYP2C8 polymorphism in populations of different 
ethnic origins from tropical areas where 4-aminoquinoline antimalarial therapy is used 
was performed in Study III and V. Alleles that lead to CYP2C8 enzymes with altered 
activities show different prevalences in the studied populations (Table 5). CYP2C8*2 is 
the most frequent variant allele in the African populations analyzed, with frequencies 
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ranging from 26.6% in Guinea-Bissau to 9.0% in Sao Tome and Principe, in contrast 
with the 3.8% observed in Colombia (population predominantly of hybrid descendence 
– “Mestizo”). For CYP2C8*3 and CYP2C8*4 a different profile was observed. In the 
case of CYP2C8*3 the highest frequency was observed for the Colombians (7.1%), 
followed by subjects from Sao Tome and Principe (4.0%) and Zanzibar (2.1%). Finally, 
CYP2C8*4 allele is present at low allelic frequencies in the studied populations, ranging 
from 1.6% in Colombia to 0.6% in Zanzibar. In Guinea-Bissau neither CYP2C8*3 nor 
CYP2C8*4 were found. In Thailand all subjects showed the wild type genotype for the 
polymorphic positions analysed. 
Concerning the data obtained for Guinea-Bissau only one of the alleles was 
observed – CYP2C8*2 (Table 5). The protein encoded by CYP2C8*2 has been 
documented to be associated to a higher Km than CYP2C8*1 (but a similar Vmax) for 
paclitaxel, which leads to a lower enzymatic activity of CYP2C8 in paclitaxel 
hydroxylation (Dai et al., 2001). A recent in vitro study using AQ as a substrate showed 
that CYP2C8*2 allele also present a higher Km, but a lower Vmax was observed (Parikh 
et al., 2007). 
In Guinea-Bissau’s population the CYP2C8*2 allele is present in the 
homozygote form in 10.4% of the individuals, so most part of the population (~ 90%) 
have a CYP2C8 enzyme that can eventually compensate the existence of a high 
frequency of    -392 A>G SNP in CYP3A4. In the fraction of the population where the 
allele is present, particularly if combined with a defective CYP3A4 enzyme, the patients 
are potentially subjected to a longer exposure to drugs metabolized by these enzymes, 
which can lead to a higher risk of adverse effects.  
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Table 5 – Genotypic Frequencies observed for CYP2C8 SNPs in the different studied populations.  
  Genotype 
CYP2C8 
792 C>G 
(I264M) 
805 A>T 
(I269F) 
1196 A>G 
(K399R) 
Zanzibar      
(n = 165) 
Portugal      
(n = 164) 
STP         
(n = 50) 
Guinea-Bissau 
(n = 96) 
Colombia    
(n = 91) 
Thailand      
(n = 116) 
*1/*1 -/- -/- -/- 0.704 0.567 0.740 0.573 0.769 1.00 
*1/*2 -/- +/- -/- 0.218 0.018 0.140 0.323 0.077 0 
*2/*2 -/- +/+ -/- 0.030  0 0.020 0.104 0 0 
*1/*3 -/- -/- +/- 0.030  0.262 0.080 0 0.099 0 
*3/*3 -/- -/- +/+ 0.006  0.043 0 0 0.022 0 
*1/*4 +/- -/- -/- 0.012  0.043  0.020 0 0.033 0 
*4/*4 +/+ -/- -/- 0 0.018 0 0 0 0 
*1/*3*4 +/- -/- +/- 0 0.037 0 0 0 0 
*1/*2*3 -/- +/- +/- 0 0.006 0 0 0 0 
*3/*4 +/+ -/- +/- 0 0.006  0 0 0 0 
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In Sao Tome and Principe malaria is also the main public health problem, 
accounting to almost 50% of the hospital deaths (http://www.theglobalfund.org/; Project 
Proposal for Malaria Control in São Tomé and Príncipe). The national antimalarial 
chemotherapy policy has recently adopted AS+AQ combination as the officially first-
line therapeutic, replacing CQ and SP. The change in the drug policy adopted is a 
consequence of the increase of drug resistance in the islands – CQ has reached a clinical 
treatment failure of 67% and SP of 20% (http://www.theglobalfund.org/; Project 
Proposal for Malaria Control in São Tomé and Príncipe). Altought the frequency of SP 
failure is low when compared with CQ, recrudescence of SP-resistance parasites were 
also associated with 6% of failure in the test of AS+SP combination. Concerning the 
data obtained for CYP2C8 in Sao Tome and Principe we observed that the alleles 
studied are all present in low frequencies (Table 5). The percentage of individuals that 
have the homozygous form of the SNPs analysed is circa 2%, and if we consider the 
population that can be exposed to antimalarial chemotherapy (CQ or AQ) it is not a 
negligible frequency that should be taken in account. 
If we compare the results of CYP2C8 genotyping from Sao Tome and Principe 
and Guinea-Bissau with the available data we can observe that CYP2C8*2 is found in 
Guinea-Bissau at high frequency (26.6%). This result contrast with the results reported 
for other African populations (Zanzibar - 13.9%, P = 0.0005; Burkina Faso - 11.5%, P = 
0.0002; Ghana - 16.8%; P < 0.0001) (Parikh et al., 2007; Röwer et al., 2005). The 
studied subjects from the islands of Sao Tome and Principe show a significantly lower 
prevalence of CYP2C8*2 allele (9.0%; P = 0.0072) and in contrast to the observed in 
Guinea-Bissau, the CYP2C8*3 and CYP2C8*4 alleles were detected in Sao Tome and 
Principe. The frequencies observed for CYP2C8*2 in Sao Tome and Principe are 
statistically different from the results in Zanzibar (P = 0.0111) and statistically 
significantly different from the frequencies in Ghana and Burkina Faso (P = 0.0019, P = 
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0.0071, respectively). These differences can be a reflection of a richer diversity in 
Africa compared with, for example, Europe where the diversity is not so evident. 
 
Countries from Central and South America also have to face the problem of 
malaria and Colombia is not an exception. P. falciparum resistance to different 
antimalarials in Colombia has been reported, namely to CQ (47% to 97%), AQ (3%–
7%) and to SP (9%–13%) (Blair et al., 2001; Osorio et al., 1999). The antimalarial 
policy in Colombia is in constant change. Anyway, the main national first line treatment 
is still in most cases the combination of the use of AQ (3 days), SP and PQ 
(www.who.int/malaria/treatmentpolicies.htm). The Colombian population consists in an 
admixture between local Indian, European (mainly from the Iberian regions) and 
Africans (Bravo et al., 2001; Salas et al., 2005). This fact is translated also in the 
frequencies observed for CYP2C8 alleles, since the pattern does not follow the 
Caucasian pattern, where CYP2C8*3 is present at high frequency, neither African 
populations where CYP2C8*2 is the predominant allele (Table 5). The CYP2C8 allelic 
frequencies observed in the Colombian setting revealed a 2% frequency of predicted 
slow metabolizers (Table 5). Although the percentage of the population at risk of a 
longer exposure to the drug seems to be low, this is relative and depending of the total 
population submitted to antimalarial therapy.  
 
In Thailand none of the studied CYP2C8 alleles were observed, in line with what 
was previously observed in Asian populations (reviewed in Gil and Gil Berglund, 
2007). Although the population has a different origin, in Papua New Guinea the 
polymorphism in CYP2C8 was also not observed (Hombhanje et al., 2005). As such, 
populations from Asian origin are expected to be all efficient metabolizers for CYP2C8 
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substrates. This typical profile can contribute to a low frequency of severe adverse 
effects associated with drugs metabolized by this enzyme, including amodiaquine. 
 
The population affected by malaria from the Zanzibar islands was the most 
thoroughly characterized from all the studied populations. Besides the aforementioned 
CYP2C8 (Study III), the main CYP1A1 and CYP1B1 polymorphisms were also 
investigated.  
The islands of Zanzibar are a setting where malaria represents a major public 
health issue. Here the first line treatment adopted is based on three doses of AS+AQ in a 
three day course (4 mg/Kg artesunate + 10 mg/Kg amodiaquine per day). Concerning 
the analysis of CYP2C8, the population studied follows the same trend subsequently 
observed in the other African populations studied, a high incidence of CYP2C8*2 
(13.9%) (Table 5). The other variants (*3 and *4) are present in lower frequencies of 
2.1% and 0.6%, respectively. The variant alleles are present in 16.6% of the analysed 
population, normally in the heterozygous form, where 3.6% corresponds to homozygous 
form. This study in the Zanzibar islands in the only one presently available in East 
African populations, being a comparison reference to studies performed in West Africa 
(previously discussed).  
The predicted number of amodiaquine slow metabolizers found in ours and other 
published works is not negligible, taking in account the incidence of malaria in the 
respective studied settings. This should be taken in account in the future pharmaco-
vigilance initiatives, in particular in frame of a possible trend of increased use of AQ 
following the recent introduction of an AS + AQ fixed combination by Sanofi-
Aventis/DNDi (http://dndi.org/pdf_files/press_release_march_1-eng.pdf).   
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In an attempt to evaluate the influence of CYP2C8 polymorphism in AQ 
efficacy we have determined the frequencies of CYP2C8 major alleles in a Zanzibar 
population where the treatment outcome was analysed after the antimalarial therapy 
with AS + AQ (Study VI - Influence of CYP2C8 polymorphism in AQ therapy). From 
the analysis of CYP2C8 genotype we observed that the genotype had no significant 
influence in the outcome (Table 6), when comparing a control group where the 
treatment was successful and another where the patients experience a recurrence of the 
infection. This was observed in AS+AQ treatment group but also in a group treated with 
AL (data not shown), the later being a negative control for the study, as CYP2C8 is not 
involved in the metabolism of these drugs.  
 
The results obtained with the populations of the Zanzibar islands treated with 
AS+AQ are in line with recently published data from an AQ monotherapy efficacy trial 
performed in Burkina Faso (Parikh et al., 2007). In that study the analysis is presented 
only for the case of CYP2C8*2 (the main allele present in native sub-Saharan African 
populations) but for the three different groups: (1) adequate clinical and parasitological 
response, (2) recrudescence and (3) new infection. Even with this stratification, 
variations in the efficacy outcome were not observed, dependent on CYP2C8 status. 
Considering the fact that presently AQ is mainly administred in combination 
with AS (with a high PRR) and it is rapidly biotransformed in DEAQ, the contribution 
of AQ in the therapy is, in fact, expected to be minimal. This can explain why in the 
population analyzed a protective effect by the different alleles was not observed. The 
present observations might change in long term, with the development of a scenario 
where the parasite has developed resistance to DEAQ. Then, an expected larger AQ 
AUC associated to subjects carrying low activity alleles will become significantly more 
influencial for the success of the therapy.     
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Table 6 - Frequencies for CYP2C8 genotypes in the two groups of Zanzibar population 
of P. falciparum malaria patients treated with AS+AQ. 
Patients with positive outcome 
(n=110) 
Patients with recurrences     
(n= 63) 
p-value 
Genotype 
n Frequency (95% CI) n Frequency (95% CI)  
*1/*1 66 0.600 (0.508 – 0.692) 38 0.603 (0.472 – 724) 0.9837 
*1/*2 36 0.327 (0.240 – 0.415) 20 0.317 (0.206 – 0.447) 0.9243 
*2/*2 3 0.027 (0.006 – 0.078) 1 0.016 (0.0004 – 0.085) 0.6385 
*1/*3 4 0.036 (0.010 – 0.090) 4 0.064 (0.018 – 0.155) 0.6866 
*1/*4 1 0.009 (0.0002 – 0.050) 0 0 (0.000 – 0.057) 0.4499 
 
 
The new data concerning the biotransformation of AQ show that the metabolism 
is impaired by the presence of CYP2C8*2 and CYP2C8*3 (Parikh et al., 2007). These 
observations had led to the prediction by the authors that in the case of both variants the 
concentration-time profiles of AQ and DEAQ could be altered. In the case of DEAQ 
however, and contrary to the hypothesised by the authors, the significant interindividual 
diversity in PK parameters observed in a study conducted in Papua New Guinea, was 
not explained by the CYP2C8 polymorphism, as all subjects were confirmed as only 
carrying the wild type allele (Hombhanje et al., 2005).  
The alterations in the concentration-time profiles of AQ and DEAQ can be 
important in the risk developing drug induced adverse events. AQ toxicity has been 
associated to the formation of a quinoneimine reactive product and DEAQ shows 
significantly reduced capacity to generate this toxic metabolite, when compared with 
AQ (Clarke et al., 1991; Jewell et al., 1995; Tingle et al., 1995). This suggests that the 
formation of DEAQ can be a pathway associated to a decreased risk for the advent of 
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quinoneimine related cytotoxic effects. In the study from Parikh and collaborators this 
issue was also evaluated and no major adverse events were reported in the population 
analyzed (Parikh et al., 2007). However, an interesting significant increase in mild side 
effects (self reported rate of abdominal pain: 52% vs 30%, P < 0.01) was detected 
among the carriers of the CYP2C8*2. To note that this allele, although with decreased 
AQ metabolism activity (significantly increased Km and decreased Vmax), is still able to 
biotransform this drug, while the CYP2C8*3 associated SNPs seems to severely affect 
the coded enzyme. In fact, the kinetic parameters of the enzyme were not possible to be 
determined, as no AQ metabolism was detected (Parikh et al., 2007). These results 
mirror the previously observed with the probe drug paclitaxel, where a decrease to 15% 
of the metabolism capacity of the “wild type” allele (CYP2C8*1) was documented (Dai 
et al., 2001). Faced with this new data, we are left to speculate if the CYP2C8*3 allele – 
more frequent among Caucasians, as we determined among the Portuguese population – 
had playing a role in AQ driven serious adverse events observed on the past among 
Caucasian travellers.   
 
The new information concerning the effect of CYP2C8 variants in the AQ 
metabolism and possible effect in efficacy and adverse events should be put in context 
to recently documented drug-drug interctions data. The inhibitory effect of different 
anti-HIV/AIDS drugs (e.g. efavirenz, nevirapine, saquinavir, lopinavir, etc) and also the 
antimalarial pyrimethamine on CYP2C8 activity has been evaluated (Parikh et al., 
2007). The antimalarial pyrimethamine was shown to inhibit CYP2C8 although in a 
range of concentrations that are not achieved in the standard dosing. More important for 
the scenario where AQ has been implemented, is the strong inhibition observed in the 
case of clinically relevant concentrations of anti-HIV/AIDS drugs efavirenz, saquinavir, 
lopinavir and tipranavir. The concomitant use of these therapeutic can lead to higher 
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concentrations of AQ and hypothetical sub-sequent increase in the toxicity.  Indeed, if 
we take into account the study performed by German and collaborators we observe that 
this hypothetical increase in the toxicity was already observed in vivo (German et al., 
2007). The results in an African American men and in a White woman show that the 
administration of efavirenz togheter with AS+AQ lead to increased levels of liver-
associated enzymes (alanine aminotransferases and aspartate aminotransferase). The 
hepatotoxicity is due the drug interaction, since it is only observed when to the 
antimalarial therapeuthic AS+AQ is added the anti-HIV/AIDS drug efavirenz (German 
et al., 2007). 
 
CYP1A1 and CYP1B1 polymorphism in Zanzibar malaria patients 
The Cytochromes P450 have been suggested to have a role in the extrahepatic 
metabolism of amodiaquine, namely CYP1A1 and CYP1B1 (Li et al., 2002). In 
accordance, a study on the variants in the genes coding for these enzymes was 
performed in patients from the Zanzibar islands.  
Concerning CYP1A1 the 2455 A>G SNP was analysed, which is representative 
of both CYP1A1*2B and *2C alleles. The analysis of CYP1A1 2455 A>G SNP shows 
that it is present in the Zanzibar population at low frequency (2.4%). This variation is 
only present in the heterozygote form (5 in 103) and was found to be in Hardy-
Weinberg equilibrium. Our studies confirm a previous study in African native 
populations showing this as a low frequency variant, with a frequency of 1.3% in 
Tanzanians, and being absent in South African Venda and Zimbabweans (Dandara et 
al., 2002). The presence of this SNP in mainland Tanzanians and in the Zanzibari 
population, but not in the other two countries might be related to the fact that in this 
Eastern African coastal regions gene mixing may have existed between the local Black 
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population and the Orientals, where 2455 A>G was described to be more frequent (~ 
20%) (Dandara et al., 2002; Chowbay et al., 2005).  
The analysis of CYP1B1 genetic variability has involved the genotyping of five 
SNPs by PCR-RFLP (4326 C>G, 4360 C>G and 4390 A>G) and sequencing (142 C>G 
and 355 G>T). Due to results in the sequencing that did not allow the unequivocal 
identification of the variants, some samples had to be excluded and the initial group 
having been consequently reduced to 82 individuals.  
The previoully referred SNPs define different alleles, CYP1B1*1, *2, *3, *4, *5, 
*6, and *7, all present in the studied population (Table 7), except for the CYP1B1*5.  
From the twelve different combinations that ocurr, the CYP1B1*2/*6 and CYP1B1*6/*6 
are the more frequent (Table 7). The high frequency of CYP1B1*2, *3 and *6 alleles is 
the result of a high frequency of the 142 C>G (70.1%), 355 G>T (70.1%) and 4326 
C>G SNPs (65.2%).  
From the SNPs analysed, three were found to be in Hardy-Weinberg 
equilibrium, 4326 C>G, 4360 C>G and 4390 A>G, but the other two did not follow the 
equilibrium. Both 142 C>G and 355 G>T are deficient in heterozygotes (15 observed vs 
34.36 expected). Since the other three SNPs are in equilibrium in the same population is 
difficult to explain these two cases, unless the two SNPs had been selected in the 
Zanzibar islands during evolution by some unknown reason. If we take into account the 
sequencing results we can see that they are very clear in the cases of homozygotes, so a 
bad interpretation of the not so clear heterozygotes only would lead to a higher number 
of the two genotypes already in “excess” (Figure 17).  
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Table 7 – Genotype and allelic frequencies of CYP1B1.  
 
CYP1B1 Genotypes (n = 82) Allele Frequencies (n = 164) 
Genotypes n Frequency (95% CI) Allele n Frequency (95% CI) 
*1/*1 4 0.049 (0.014 – 0.120) CYP1B1*1 20 0.122 (0.072 – 0.172) 
*1/*2 2 0.024 (0.003 – 0.085) CYP1B1*2 36 0.220 (0.156 – 0.283) 
*1/*3 5 0.061 (0.020 – 0.137) CYP1B1*3 28 0.171 (0.113 – 0.228) 
*1/*4 1 0.012 (0.0003 – 0.066) CYP1B1*4 1 0.006 (0.0002 – 0.034)
*1/*6 4 0.049 (0.014 – 0.120) CYP1B1*6 75 0.457 (0.381 – 0.534) 
*2/*2 7 0.085 (0.035 – 0.168) CYP1B1*7 4 0.024 (0.007 – 0.061) 
*2/*6 20 0.244 (0.156 – 0.351)    
*3/*3 7 0.085 (0.035 – 0.168)    
*3/*6 7 0.085 (0.035 – 0.168)    
*3/*7 2 0.024 (0.003 – 0.085)    
*6/*6 21 0.256 (0.166 – 0.364)    
*6/*7 2 0.024 (0.003 – 0.085)    
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The studies in African origin populations are scarce concerning the CYP1B1 
gene, being an Ethiopian population the only African native population analysed 
(Aklillu et al., 2002). When we compare the genotypes observed in Zanzibar with the 
reported by Aklillu and collaborators we can see that Zanzibar does not present many 
different genotypes (12 vs 18 in Ethiopia). The genotypes described for each population 
are arranged differently and with different frequencies. In Zanzibar the most frequent 
genotype (Table 7) is CYP1B1*6/*6 (25.6%) followed by CYP1B1*2/*6 (24.4%), 
frequencies statistically different from the 0.7% and 5.3%, respectively, observed in 
Ethiopia (P < 0.0001). The most frequent genotype among Ethiopians, CYP1B1*2/*3 
(29.3%), was not found in our study in Zanzibar. In terms of allelic frequency, 
differences are also evident, since in the case of Zanzibar the more frequent allele is 
CYP1B1*6 with 45.7% and CYP1B1*2 (22.0%), while in Ethiopia the highest 
frequency was observed for CYP1B1*3 (39.0%), followed by CYP1B1*2 with 36.7% 
(Aklillu et al., 2002).  These differences may be due to differences in the origins of the 
studied population, since Zanzibar islands should have more gene mixing than the 
population in Ethiopia (http://www.zanzinet.org/). 
 
Considering the hypothetical role of CYP1A1 and CYP1B1 in the extrahepatic 
metabolism of AQ, the results here presented show a high variability that could have an 
influence in the metabolism of this drug. Unfortunally, the controversy behind the effect 
of the SNPs, namely in the case of CYP1A1, and the lack of a complete analysis of the 
in vivo functional consequences of the CYP1B1 haplotype, does not allow a theoretical 
prediction of the effect of polymorphisms in CYP1A1 and CYP1B1 in AQ therapeutics.  
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a) 142 CC 
 
 
 
b) 355 GG 
 
 
 
c) 142 CG 
 
 
d) 355 GT 
 
 
e) 142 GG 
 
 
f) 355 TT 
 
 
Figure 17 – Example of the results obtained in the sequencing of CYP1B1 142 C>G and 
355 G>T SNPs. The arrows indicate the position of the SNPs. 
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The pharmacogenetic characterization of the population of Zanzibar concerning 
other important proteins in the metabolism of antimalarials was performed in a parallel 
study not included in this thesis (Ferreira et al., submitted, Other Publications). In this 
study the DNA from the children previously analysed for CYP2C8 was studied for the 
main functionally relevant SNPs present in genes potentially involved in the elimination 
of other central antimalarial drugs in current use in Zanzibar. The genes included in this 
study were the cytochrome P450s CYP3A4, CYP3A5, CYP2B6, the MDR1 transporter 
and the nuclear receptor PXR. From all the variants analysed, CYP3A4*1B allele was 
the more frequent being present in 49.5% of the patients in the homozygous form. The 
other alleles analysed coding for low activity proteins were found in the homozygous 
form in frequencies ranging from 2.9% in MDR1 to 14.6% in CYP3A5. An important 
result in the analysis was the fact that ten subjects were found to be predicted low 
metabolizers simultaneously for CYP3A4 and CYP3A5, which can be a major problem 
in the case of antimalarial drugs where the metabolism is mainly performed by these 
enzymes (e.g. quinine, mefloquine and LUM). In this study, regions of MDR1 and 
CYP3A4 promoters associated to the transcriptional control of these genes were 
sequenced. In PXR the sequencing was performed in the exons 2 and 5, coding part of 
the functionally important DNA binding domain (DBD) and Ligand Binding Domain 
(LBD) (Lamba et al., 2005). From this analysis only one SNP, previously described 
(Zhang et al., 2001), was observed (79 C>T, P27S) in a frequency of 11.2%, showing 
that these two exons are highly conserved. In MDR1 a new SNP was found, –158 T>C 
(tagtcatgT/Cactcaaaa) with a prevalence of 7.3%. 
This study completes – for the moment – the picture of the main 
pharmacogenetic factors that can influence potential toxicity of the antimalarial drugs 
on the islands of Zanzibar. The Zanzibar population is now one of the best characterized 
African native populations in terms of pharmacogenetic determinants. 
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Study VII - Ethnic distribution of CYP3A5 and PXR polymorphism 
 
The CYP3A5 enzyme was recently described has having a role in the 
metabolism of quinine (Rodriguez-Antona et al., 2005), but at the time this study 
started, the CYP3A5 gene, in particular the 6986 A>G SNP was choosen because the 
carriers of this mutation appear to be defective in CYP3A5 enzyme. The high frequency 
of this variant in Caucasian when compared with the African-Americans was also taken 
in account to choose this SNP. 
In order to evaluate the distribution of CYP3A5 6986 A>G SNP, which defines 
CYP3A5*3 and the minor alleles *10 and *11, we analysed the same groups of subjects 
previously analysed for CYP2C8 from the populations of Guinea-Bissau, Sao Tome and 
Principe, Thailand and Portugal. The CYP3A5 6986 A>G SNP is present in all the 
populations analysed with the Portuguese population being the carrier of the highest 
frequency of the variant (86.9% in the homozygous form). The other populations 
studied presented lower frequencies (Table 8), particularly the African populations with 
frequencies that reach as low as 5.3% of subjects homozygous for the G allele in the 
case of Guinea-Bissau.  
In Figure 18 the world distribution of the 6986 A>G SNP is presented. We can 
see that the frequencies obtained for the Portuguese and Thai population are similar to 
the ones reported for other Caucasians and Asian populations. The same does not 
happen in Africa where there are significant differences between the populations 
analysed up to date. 
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Table 8 – Genotypic frequencies for the SNPs analysed in CYP3A5 and PXR genes in the studied populations. 
 
CYP3A5 
6986 
PXR 
7635 
PXR 
8055 
PXR 
11156 
PXR 
11193  
A/A A/G G/G A/A A/G G/G C/C C/T T/T A/A A/C C/C T/T T/C T/T 
Portugal 
(n= 61) 
0.164 0.115 0.869 0.328 0.443 0.229 0.590 0.328 0.082 0.590 0.328 0.082 0.590 0.328 0.082 
Thailand 
(n= 116) 
0.190 0.483 0.328 0.052 0.517 0.431 0.164 0.664 0.172 0.164 0.664 0.172 0.164 0.664 0.172 
STP 
(n= 50) 
0.380 0.400 0.220 0.020 0.260 0.720 0.420 0.440 0.140 0.220 0.600 0.180 0.220 0.600 0.180 
Guinea-Bissau 
(n= 95) 
0.610 0.337 0.053 0 0.011 0.989 0.316 0.537 0.147 0.200 0.558 0.242 0.200 0.558 0.242 
 
  95
The percentages of 6986GG carriers reflect the population where the CYP3A5 
enzyme is not present. From the results in the Portuguese population it is clearly evident 
that CYP3A mediated metabolism should be particularly mediated by CYP3A4 with a 
minor contribution of CYP3A5. The same happens, to a lesser extent in the Thai 
population. However a completely different scenario is observed in Guinea-Bissau and 
Sao Tome and Principe (and Zanzibar) where a variable degree of CYP3A5-mediated 
metabolism should be present. 
The low frequency of individuals carrying the 6986 A>G SNP in Guinea-Bissau 
indicates that probably the majority of the persons express the CYP3A5 enzyme. The 
role of CYP3A5 enzyme in the metabolism of CQ has not been clearly elucidated (Li et 
al., 2003), so it is conceivable that CYP3A5 could share this substrate with CYP3A4. 
Although the inexistence of acute toxicity with the higher dosage of CQ used in Guinea-
Bissau cannot be related directly with a genetic cause (Kofoed et al., 2007; Ursing et 
al., 2007b), it should be of interest to evaluate the relative contribution of different 
expression levels of the CYP3A enzymes.  
On the other phenotypic extreme, if we analyse the results of CYP2C8 and 
CYP3A5 together, we find that seven individuals have defective SNPs in both genes. 
This means that 7.4% of the analysed population is hypothetical low metabolizers (or 
intermediate, depending of the alleles) concerning these enzymes. We have also to take 
into account the fact that a higher percentage of the population bears the defective 
CYP3A4*1B.  
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Figure 18 – CYP3A5 6986 A>G SNP world distribution (map adapted from http://www.colby.edu/ 
geology/gifs/worldmap.gif) (data from Kuehl et al., 2001; Hustert et al., 2001b; Roy et al., 2005; 
Gervasini et al., 2005; King et al., 2003; Koch et al., 2002; Wadelius et al., 2004; Thervet et al., 
2003; van Schaik et al., 2002; Balram et al., 2003; Fukuen et al., 2002b; Dandara et al., 2005; 
Wojnowski et al., 2004; Ferreira et al., in press, Other Publications; Veiga et al., submitted, Other 
Publications). 
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In Sao Tome and Principe the frequency of individuals homozygous for CYP3A5 
6986 A>G SNP was 22.0% (Table 8), significantly higher than the observed for Guinea-
Bissau (P = 0.0006). This difference might reflect the percentage of native Africans 
present in the two countries - in Guinea-Bissau around 99% but less in Sao Tome and 
Principe, since the “Mestizo” is a significant part of the population.  
The word “Mestizo” is normally connected to a person of mixed race, which 
means, by example, in Mexico and Central and South America, a person of European 
(Spanish or Portuguese) and indigenous descent (Columbia Encyclopedia, Columbia 
University Press). In the case of Sao Tome and Principe the islands were uninhabited 
before the Portuguese explorations and the majority of the current population is 
descendent from the mixing of the Portuguese that initially settled the islands from the 
15th Century onwards and the slaves brought from Africa mainland to work in 
agriculture (Tomas et al., 2002). 
When we analyse the presence of CYP2C8 and CYP3A5 defective alleles in the 
same individuals we observe that 3 in 50 carry mutations in both genes, and may 
therefore present an impaired metabolism.   
In Thailand the allelic frequency for CYP3A5 6986 A>G SNP was determined to 
be 56.8% and a high percentage is present in the homozygous form (32.8%) (Table 8).  
The allelic frequency observed is very similar to the frequencies reported in Malaysia 
and Vietnam, nearby countries (Figure 17). Contrary to CYP2C8 where the Asian 
populations seem to be normal metabolizers, for CYP3A5 a high fraction of the 
populations do not have the enzyme and another important fraction has lower levels of 
this enzyme. The frequencies described in these Asian countries for CYP3A5 6986 A>G 
SNP are between the two extremes observed in populations from African and Caucasian 
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origin. Like in Caucasians, in the Asian populations the clearance of drugs which are 
CYP3A substrates should be mediated mainly by CYP3A4.  
The variation that is observed around the world in terms of CYP3A5 6986 A>G 
SNP frequency will be translated in a high degree of variation in the expression of the 
enzyme. This variation in expression may be a genetic contributor to taking into account 
in interindividual and interracial differences that have been reported in CYP3A-
dependent drug clearance. 
 
All the genes previously discussed (except NAT2) are regulated (directly or not – 
CYP1 family is regulated indirectly via the receptor AhR) by the nuclear receptor PXR. 
Several highly prevalent variants in PXR gene were described in 2001 by Zhang and 
collaborators and among them we choose to study four, 7635 A>G, 8055 C>T, 11156 
A>C and 11193 T>C, all associated with a phenotypic alteration and non-negligible 
frequencies (Zhang et al., 2001). The SNPs analysed were found to be present in all the 
populations and normally in high frequencies, particularly in African populations (Table 
8). We observed that two of the studied SNPs are in complete linkage (11156 A>C and 
11193 T>C) in all the populations (Table 8). In Portuguese and Thai populations 
another SNP, 8055 C>T, appears in linkage with these two.  
 
Regarding the results obtained in Guinea-Bissau all the PXR SNPs studied are 
present in frequencies above 50% (Table 8). The more frequent is 7635 A>G present in 
98.9% of the studied population as G/G homozygote. This SNP (and also 8055 C>T) 
were described as being associated with a higher induction activity of PXR (Zhang et 
al., 2001). As such, they may lead to higher levels of expression of the genes involved 
in the metabolism of CQ (CYP2C8 and CYP3A4). 
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Concerning the two SNPs localized in the 3’ untranslated region, 11156 A>C 
and 11193 T>C, these were observed in a complete linkage at high frequencies. These 
two SNPs were correlated with decreased P-gp levels in the gut (Zhang et al., 2001) 
which potentially can alter the bioavailability and pharmacokinetic profile of substrates. 
Decreased P-gp levels might contribute to an increase in the absorption of orally taken 
antimalarial drugs.  
 
We performed a haplotype analysis for the analysed SNPs of PXR using the 
PHASE Version 2 software (Stephens et al., 2001; Stephens and Donnelly, 2003; 
http://stephenslab.uchicago.edu/software.html). This analysis led to the identification of 
eight possible different haplotypes for PXR (Table 9). In Guinea-Bissau all the possible 
haplotypes were present, although four of them are predicted to be present in low 
frequency. This is in contrast with Portugal where only three of the haplotypes were 
estimated to be present and all in high frequencies (Table 9). These differences may be a 
consequence of the complete linkage that is observed between two of the SNPs for 
Guinea-Bissau and three SNPs for Portugal. The diversity observed in Guinea-Bissau in 
terms of haplotypes is a somewhat expected phenomenon, in the light of the fact that the 
modern humans are known to have evolved from African ancestors (Forster, 2004). It 
has been proposed that ancestral alleles are "African", in the sense that these are 
expected to reach their highest diversity and frequency in natives of that continent (Satta 
and Takahata, 2002; Takahata et al., 2001). 
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Table 9 - Haplotypes for PXR and their estimated frequencies in the studied 
populations. 
Nucleotide Position 
Haplotype 
76
35
 
80
50
 
11
15
6 
11
19
3 
Po
rt
ug
ue
se
 
T
ha
i 
ST
P 
G
ui
ne
a-
B
is
sa
u 
1 A C A T 0.549 0.310 0.149 0.001 
2 A C C C - - 0.001 0.001 
3 A T A T - - - 0.001 
4 A T C C - - - 0.002 
5 G C A T 0.205 0.186 0.335 0.344 
6 G C C C - 0.004 0.156 0.238 
7 G T A T - - 0.036 0.133 
8 G T C C 0.246 0.500 0.323 0.280 
 
A very interesting observation was the strong association of CYP3A5 6986 A>G 
SNP with PXR variants, with 67% of Portuguese bearing at least one G in conjunction 
with one PXR variant. The same phenomenon was observed in 76% of subjects from 
Thailand, 60% in Sao Tome and Principe and 39% in Guinea-Bissau. It is tempting to 
speculate that carriers of a low CYP3A5 expression will, in a significant number of 
cases, harbour an increase in CYP3A4 expression, due to the linked PXR polymorphism 
reflecting a possible selected compensatory effect.  
By contrast we have detected subjects bearing the “wild-type” CYP3A5 
(individuals that express CYP3A5) in conjunction with one or more PXR variants 
associated to increased PXR transcriptional activity. These individuals are expected to 
possess a higher CYP3A-mediated metabolic activity, either basal or after exposure to 
known PXR activators. In the populations analyzed the association was found with a 
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frequency of 19% in subjects from Thailand, of 38% in Sao Tome and Principe and of 
61% in Guinea-Bissau. None of the Portuguese Caucasians were found to bear these 
characteristics. These different allele combinations probably implicate significant 
interindividual differences in drug clearance, an hypothesis yet to be tested.  
 
The description that artemisinin drugs are activators of PXR and CAR revealed 
that a vast list of genes may be affected by exposure to this drug. In the report of Burk 
and collaborators it was shown that ART activates human PXR and can induce 
CYP3A4, CYP2B6 and MDR1 mRNA expression (Burk et al., 2005). The activity of P-
gp was demonstrated to be partially inhibited by ART but in the case of CYP3A4 this is 
only suggested (Burk et al., 2005). A strong induction effect of ART was observed in 
vivo in which concerns the mouse Cyp2b10, both at mRNA and enzyme activity levels 
(the same was unable to be shown for Cyp3a) (Simonsson et al., 2006), pointing to a 
regulator role only of CAR (since it was not observed in vitro activation of PXR). More 
recently, however, it was demonstrated that artemisinin antimalarials are inducers of 
CYP3A (Asimus et al., 2007). These two reports are, in some way, contradictory since 
only Burk and collaborators see an activation of PXR after the treatment with ART 
(Burk et al., 2005), which may be the result of different experimental approaches.  
 
However, considering the regulatory role of PXR and the fact that it is activated 
by ART, the massive introduction of ACT may bring serious problems concerning drug-
drug interactions, efficacy and adverse effects. CYP3A4, as an example, is the enzyme 
responsible for the metabolism of different antimalarial drugs (see Malaria – 
Antimalarial drugs for details). If we look to the implementation of ACT, one of the 
most used combinations is artemether + lumefantrine (see Figure 5), both drugs 
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metabolized by CYP3A4. Since artemether was demonstrated to activate PXR and to 
induce PXR and CYP3A (Burk et al., 2005; Asimus et al., 2007), the use of a 
combination where the two drugs are substrates for CYP3A4 enzyme can be a problem. 
This situation can lead to a decrease in the efficacy of the therapeutic and, 
hypothetically, to the development of resistance since subtherapeutic levels of the drugs 
can be reached. However, CYP3A4 is also responsible for the metabolism of many 
other drugs, including many anti-HIV drugs and in the scenario already mentioned of 
co-infections (malaria and HIV/AIDS) this can result in important drug-drug 
interactions that have to be evaluated. With the recent report of hepatotoxicity resulting 
from drug interaction because of administration of AS + AQ and efavirenz (German et 
al., 2007) the evaluation of resulting adverse effects is even urgent. In these cases it 
should be interesting to analyse also the role of the different PXR polymorphisms and 
see if they lead to a reduction (or increase) in the induction effect, and consequently of 
the drug-drug interactions. The effect of PXR activation by ART in the expression of 
other CYPs involved in the metabolism of antimalarials, as is the case of CYP2C8, was 
not determined yet.  
 
Taken together, our results show a very high prevalence of PXR SNPs and a 
strong association between CYP3A5 and PXR polymorphic loci in African populations, 
strengthening the idea that ethnic differences may be important, and must be 
documented in order to better understand and eventually optimize therapeutic outcome.  
 
Generally, the results obtained in the genotyping studies show the variability that 
exists between different continents, a fact already observed in the many genetic studies 
performed during the last decades. A relatively new observation is the variability that 
exists in the same ethnic group, which is particularly true in the case of the Africans. 
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Factors like the concomitant use of anti-HIV drugs, anti-TB, or many other drugs and 
herbal compounds (the reality in Africa) are normally not taken into account during the 
clinical trials and many of the adeverse effects, or even deaths, can be the result of drug-
drug interactions and not from the disease. The problem of drug-drug interactions has 
also to be considered because of the possibility of diminishing the therapeutic efficacy 
of chemotherapy.    
 
 
 
Metabolic pathways of DEAQ – The role of CYP1A1 
 
In the in vitro assay for DEAQ metabolism in human liver microsomes, no 
variations were observed in concentrations of DEAQ, pointing at one of several 
outcomes: (1) the drug is not metabolized in vivo; (2) it is metabolized so slowly that 
the incubation times of this type of in vitro system are not efficient enough to detect it; 
(3) it is metabolized by a non-hepatic expression enzymes. The incubation with 
microsomes enriched with CYP1A1 (InVitroSomes™, InVitro Technologies, Inc., 
Baltimore, Maryland, USA) revealed a decrease in the concentration of DEAQ. This 
was not observed with other recombinant enriched microsomes.  
The CYP1A1 enzyme had been previously suggested to mediate the in vitro 
biotransformation of DEAQ (Li et al., 2002). In order to evaluate the in vivo 
contribution of CYP1A1 genetic variation as a basis for the interindividual variability in 
pharmacokinetic (PK) parameters observed previously in patients from Papua New 
Guinea (Hombhanje et al., 2005) and Zanzibar (Friberg Hietala et al., 2007) we 
sequenced the full coding region of CYP1A1 gene and a small region of the proximal 
promoter from these subjects.  
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Significant sequence variation was detected among the Papua New Guinea 
subjects, although not associated to the documented PK data (Table 10). The high 
diversity of SNPs found among the Papua New Guinea subjects led us to confirm a 
subset of them through another robust technique. Pyrosequencing of the promoter 
located SNPs -92 A>T, -86 C>G and -80 T>G revealed them as probable sequencing 
artifacts. All the other nucleotide changes founded during sequencing should be also 
verified to confirm the results obtained.  
 The Zanzibar samples only harboured two SNPs, 233 T>C (already described 
before) and 3309 A>G (intronic), both not related to the available pharmacokinetic data 
(Sofia Friberg Hietala, Göteborg University, manuscript in preparation). Interestingly, 
this low variation is concomitant with preliminary data indicating low variation on the 
PK parameters of DEAQ among the studied Zanzibari population (e.g. interindividual 
AUC variantions not larger that 30% (Sofia Friberg Hietala, Göteborg University, pers. 
commun). The hypothesis stays open that the higher diversity detected among the 
Papua New Guinea patients might be related to not detected, but functionally important 
linked SNPs (e.g. in distant regulatory regions of the gene). 
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Table 10 – Nucleotide changes detected by the analysis of the results of the sequencing of CYP1A1 in the samples from Papua New Guinea. The position 
considers the ATG has the +1 nucleotide.  
 -63 
G>A 
-57 Ins 
G-56 
134 
G>A 
167 
G>A 
354 
T>A 
3303 
G>A * 
3335 
G>A * 
3486 
G>A * 
3534 
G>A * 
4508 
A>G 
4588 
G>A * 
4597 
C>T * 
4633 
T>C * 
t1/2 
(days)a 
1 - x - - - ? ? - - - - - - 3.5 
2 x x - - - x x - - - - - - 3.3 
3 x x  - - x x - - - - - - 6.7 
4 - - - - - ? ? - -     8.4 
5 - - - - - x x x x     3.4 
6 - - - x x x x x -     7.7 
7 - - - - - x x - -     7.9 
8 - - - - - x x - x     9.3 
9 - - x - - x x - x     30.5 
10 - - - - - x x - x  x  x 8.8 
11 - - - - - x x - - x  x  5.1 
12 - - - - - x x - -     23.6 
13 - - - - - x x x x  x   5.1 
14 - x - - - x x - -     13.3 
15 x x - - - x x - -  x   7.1 
16 - - - - - x x - - - x   4.2 
17 x x - - - x x - -   ? x 6.8 
18 x x - - - x x - - x x   10.6 
19 - - - - - x x - -  x   10.1 
* These SNPs are localized in introns. a Data  from Hombhanje et al., 2005. The sequencing was made without knowledge of the pharmacokinetic data. Only 
after the analysis was finished the match was made with the information provided by Prof. Akira Kaneko (Karolinska Institutet). 
  106
Study VIII - The role of GSTM1 and T1 in uncomplicated malaria  
 
The antioxidant system, which includes gluthatione S-transferases, plays an 
important role in malaria. The deletion of two of these enzymes, GSTM1 and GSTT1 
was analysed in the context of uncomplicated P.falciparum malaria. We found an 
extremely significant higher frequency of GSTT1 null genotype in the control patients 
when compared with malaria patients (45.4% vs 21.5%) (Table 11). No difference was 
observed in the case of GSTM1, as can be seen by the odds ratio observed for each case 
(GSTM1 - 0.978 (0.773–1.24) and GSTT1 - 0.328 (0.259–0.417)).    
These results suggest that GSTs may have a role in malaria susceptibility, 
especially GSTT1 since the lack of this gene seems to be a protective factor in 
uncomplicated malaria. Accordingly, some data show that drugs that decrease the 
oxidative stress can increase the parasitemia in malaria patients (Brandts et al., 1997). 
The hypothesis that GSTT1 deletion may be a protective factor in uncomplicated 
malaria is supported by the fact that GSTT1 is highly expressed in erythrocytes 
(Schroder et al., 1996), while GSTM1 is not present (having serve in this exploration as 
a putative negative control). The expression of GSTT1 enzyme in the erythrocytes helps 
to decrease the levels of oxidative stress, probably by the conversion of peroxides that 
can damage the cell membrane. If the gene is lacking, by consequence the enzyme is not 
expressed and is not possible to conjugate the GSH with ROS, leading to higher levels 
of oxidative stress. This can further lead to non viability of the erythrocyte, and/or 
might contribute to the elimination of parasited RBCs through the oxidative stress 
associated to the phagocytosis processes.  In fact, and possible due to its haemoglobin 
based metabolism, parasite is very sensitive to ROS during its intra-erythrocyte cycle, a 
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characteristic which is thought to contribute to the efficacy of antimalarial drugs, such 
as CQ or AQ. 
The lacking of an association between GSTM1 genotype and uncomplicated 
malaria served as a control of the results obtained, since GSTM1 is expressed in 
lymphocytes but not in the erythrocytes (Wang et al., 2000). An interesting fact is the 
description of GSTM1 expression in brain (Takahashi et al., 1993), which can be 
related to the results observed in the case of severe malaria (Kavishe et al., 2006).   
 
Table 11 – The distribution of GST genotypes and odds ratio  
Control Patients 
(n=370) 
Malaria Patients 
(n= 1515) 
OR (95% CI) p-value 
Genotype* 
n Freq n Freq   
GSTM1     
Positive 233 0.630 962 0.635   
Null 137 0.370 553 0.365 0.978 (0.773–1.24) 0.8982 
GSTT1     
Positive 202 0.546 1190 0.785   
Null 168 0.454 325 0.215 0.328(0.259–0.417) <0.0001 
GSTM1/GSTT1     
Positive 305 0.824 1370 0.904   
Both Null 65 0.176 145 0.096 0.497(0.361–0.682) 0.0002 
*The subjects were classified as either positive - when at least one copy of the gene was 
present - or null genotypes. 
 
Further research is ongoing or planned (Malaria Research Unit, Karolinska 
Institutet) in order to obtain a more complete picture of the influence of GSTT1 in 
malaria pathology.  
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SUMMARY AND CONCLUSIONS 
 
• CYP3A4 and MDR1 SNPs were analysed in the Portuguese population for the 
first time in an extensive and coordinated way. The degree of linkage between 
3435 C>T and 2677 G>T presents significant differences when compared with 
previous reports. 
 
• The analysis of CYP3A4*1B and NAT2 191 G>A in Guinea-Bissau revealed 
high allelic frequencies (72.0% and 19.2%, respectively). This numbers follow 
the trend of a high prevalence of both variants in populations of African origin. 
 
• The study of the genetic variability in CYP2C8 in populations of different ethnic 
origins showed significant differences in the prevalence of the studied alleles. 
CYP2C8*2 revealed to be significantly more frequent in the African populations 
(Guinea-Bissau – 26.6%, Sao Tome and Principe – 9.0% and Zanzibar – 13.9%) 
when compared with Colombia (3.8%) and Portugal (1.2%).  CYP2C8*3 
showed the inverse trend with the Portuguese presenting the highest frequency 
(19.8%), followed by the Colombians (7.1%) and after the African populations 
(Sao Tome and Principe – 4.0%, Zanzibar – 2.1%). CYP2C8*4 is the less 
frequent allele with a frequency of 6.4% in the Portugal, 1.6% in Colombia, 1% 
in Sao Tome and Principe and 0.6% in Zanzibar. In Thailand none of the studied 
alleles were present and in Guinea-Bissau CYP2C8*3 and CYP2C8*4 are 
absent.  
 
 
 
  109
• CYP1A1 2455 A>G was shown to be present in 2.4% of the studied population, 
in the line of previous reports that points to its low prevalence in the African 
populations. Concerning the analysis of CYP1B1 polymorphism a high 
variability was observed in terms of SNP, genotype and haplotype.  
 
• CYP3A5 6986 A>G reveals a high prevalence in the Caucasian Portuguese 
population (93%) in a clear contrast with the numbers observed in Africa 
(Guinea-Bissau – 22% and Sao Tome and Principe – 42%). Thailand showed an 
intermediate frequency of 57%. The role of CYP3A5 in the metabolism of 
antimalarials (also in anti-HIV/AIDS and anti-TB drugs) is being clarified, an 
important step as in Africa the predicted high frequency of expressors of this 
gene may may lead to low therapeutic efficacy of its drug substrates.  
 
• The PXR SNPs analysed are present in high frequencies, particularly in African 
populations. Different degrees of linkage were observed between the SNPs 
analysed in the different populations characterized. The studied SNPs are 
reported to be linked with alterations in transcription rates and protein levels, so 
the role of the alterations in the metabolism of the different antimalarials should 
be clarified. 
 
• CYP1A1 was preliminary identified as the enzyme responsible for the in vitro 
metabolism of DEAQ. The analysis of CYP1A1 genetic variation contribution to 
the pharmacokinetic variability did not reveal a precise gene alteration/PK 
parameters association; although the available data suggests that marked 
interindividual variation of the later is associated with higher genetic diversity. 
This point for the possible presence of pivotal unknown genetic associations not 
unveils by our approach in this work.  
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• The GSTT1 null genotype is suggested to play a protective role in malaria 
susceptibility, with a significantly high frequency in the control group (45.4% 
vs. 21.5%, OR = 0.328 (0.259–0.417)).     
 
 
Taking into account the variability shown for the different countries, in particular 
in Africa, the role of the human host in malaria therapeutics should be more considered.  
In the African countries clinical trials should include not only the genotyping of P. 
falciparum in order to assess the level of resistance, but also of the human host. These 
studies could be useful in the evaluation of the role of genetic polymorphism in the 
therapeutic outcome, not only in terms of efficacy of the antimalarial treatment but also 
in the identification of secondary effects associated with toxicity and/or drug-drug 
interactions. This last issue is also of great importance in the African scenario where 
normally malaria, TB and HIV/AIDS are concomitant diseases.  
 The pharmacogenetic of a population can potentially influence the 
pharmacokinetics parameters of a drug. The alteration of PK parameters can led to the 
existence of subtherapeutic concentrations of drugs and this can modudulate the 
development of resistance. A better knowlgement of the pharmacogenetic of the human 
population can give a help in the long fight against one of the most important parasitic 
diseases – MALARIA.  
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